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2017.—Epithelial cells line the entire surface of the gastrointestinal tract and its
accessory organs where they primarily function in transporting digestive enzymes,
nutrients, electrolytes, and fluid to and from the luminal contents. At the same time, epithelial cells
are responsible for forming a physical and biochemical barrier that prevents the entry into the body
of harmful agents, such as bacteria and their toxins. Dysregulation of epithelial transport and
barrier function is associated with the pathogenesis of a number of conditions throughout the
intestine, such as inflammatory bowel disease, chronic diarrhea, pancreatitis, reflux esophagitis,
and cancer. Driven by discovery of specific receptors on intestinal epithelial cells, new insights into
mechanisms that control their synthesis and enterohepatic circulation, and a growing appreciation
of their roles as bioactive bacterial metabolites, bile acids are currently receiving a great deal of
interest as critical regulators of epithelial function in health and disease. This review aims to
summarize recent advances in this field and to highlight how bile acids are now emerging as exciting
new targets for disease intervention.
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I. INTRODUCTION
Bile acids, classically known for their roles in facilitating the
digestion and absorption of dietary lipids, are now also
appreciated as a family of enteroendocrine hormones that
have important roles in regulating many aspects of mam-
malian physiology, both within and outside the intestinal
tract. Driven largely by the discovery of two new bile acid
receptors at the turn of the millennium, the past two de-
cades have seen a renaissance in research activity that has
firmly placed bile acids as being central to maintenance of
our overall health. Disruptions to the processes that control
the synthesis, recycling, and excretion of bile acids are as-
sociated with the onset of many diseases that can affect the
intestine, its accessory organs, and beyond. Significant
progress has beenmade in understanding various molecular
mechanisms involved, and there is a rapidly growing inter-
est in developing our capacity to target such pathways for
disease treatment. Such an idea can hardly be considered as
being new, given that as long as 2500 yr ago, bile was
considered as comprising two of the four “humors” (black
bile and yellow bile) upon which Hippocrates established
his long-held system of human medicine (510), while ani-
mal gall has been used for centuries in Traditional Eastern
Medicine to treat many different ailments (483). However,
along with the discovery of new receptors for bile acids,
recent years have also seen a growing appreciation of how
important these molecules are to human physiology in
health and disease. This appreciation has sparked renewed
interest in the potential use of bile acids as therapeutic
agents.
Central to developing our understanding of how bile acids
can be therapeutically exploited is an understanding of how
they interact with epithelial cells throughout the intestinal
tract. These cells line the entire gut and its accessory organs
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and, as the interface between the body and the luminal
contents, they are primary effectors of bile acid-induced
responses, whether they be intestinal, hepatic, or metabolic.
While other reviews have covered recent developments with
respect to bile acids in regulation of hepatic and metabolic
function (97, 111, 151, 252, 370, 463), the current manu-
script aims to provide an overview of how luminal bile acids
interact with gastrointestinal epithelial cells, the implica-
tions of such interactions for our physiology, and how we
can ultimately target these fascinating molecules for the
treatment of disease.
II. BILE ACID PHYSIOLOGY
A. Bile Acid Synthesis and Metabolism
Since this review is primarily concerned with the physiolog-
ical effects of bile acids on extrahepatic epithelia, we aim to
include only a broad overview of the processes involved in
their biosynthesis and metabolism. For more detail, readers
are directed to excellent reviews previously published on
this topic (328, 390). Essentially, epithelial cells along the
intestinal tract can come into contact with either primary
and/or secondary bile acids, which are either in their con-
jugated or unconjugated forms. Primary bile acids are syn-
thesized from cholesterol by hepatocytes in the liver
through complex enzymatic pathways, with the rate-limit-
ing step being the enzyme CYP7A1. In humans, the primary
bile acids are cholic acid (CA) and chenodeoxycholic acid
(CDCA). However, it should be noted that other primary
bile acids are synthesized in different species, such as
muricholic acid in mice and hyocholic acid in pigs (168),
and that these bile acids can have dramatically different
bioactivities from those of CDCA and CA. Thus it is impor-
tant to keep this in mind when translating experimental
data from animal models into humans.
After their biosynthesis, primary bile acids are conjugated
to either taurine or glycine. Inmost vertebrates, conjugation
is with taurine, but in humans, glycine conjugation predom-
inates. Glutathione conjugates have also been identified in
bile, but only in trace amounts (303). Conjugation involves
formation of a bile acid coenzyme A ligase (which activates
the carboxyl group) and an amino transferase, in which the
CoA thioester links the carboxyl group of the bile acid to
the amino moiety of taurine or glycine to form a stable
amide bond. Conjugation lowers the pKa of bile acids and
therefore has important consequences for their physico-
chemical properties and their biochemical and physiologi-
cal actions, making them fully ionized at the pH of luminal
contents of the proximal small intestine (170, 385). Thus,
unless a transporter is present, conjugated bile acids are
impermeable to epithelial cell membranes, permitting high
luminal concentrations to be achieved in the biliary tract
and proximal small intestine, thereby enabling micellar sol-
ubilization of dietary lipids to occur (409).
Within the intestinal lumen, particularly in the colon, pri-
mary bile acids are extensively metabolized by the resident
microbiota into secondary bile acids, first by hydrolysis of
their amide bond and subsequently by modifications to the
hydroxy groups on their steroid nucleus (383). Deconjuga-
tion is the gateway reaction to further bile acid metabolism
and is carried out by bile salt hydrolases (BSH), enzymes
that are widely expressed by gram positive, and some gram
negative, bacteria within the gut lumen. Several isoforms of
BSH exist which differ in their substrate specificities but
which tend to have a higher affinity for glycine-conjugated
bile acids (58, 200, 265). Resistance to bile acid toxicity is
an important characteristic enabling bacterial survival
within the gut lumen, and different species have different
sensitivities to conjugated and deconjugated bile acids.
Therefore, the pattern of expression of BSHs plays a vital
role in shaping the makeup of the luminal microbiota, while
at the same regulating the capacity of bile acids to penetrate
epithelial membranes, activate their receptors, and induce
biological responses.
Upon deconjugation, the hydroxyl groups at positions 3, 7,
and 12 of the steroid nucleus can then be subjected to me-
tabolism by a number of bacterial enzymes, including de-
hydroxylases, dehydrogenases, and epimerases. For exam-
ple, CA is dehydroxylated at position 7, to yield DCA, a
dihydroxy bile acid, whereas 7-dehydroxylation of CDCA
yields LCA, a monohydroxy bile acid. DCA and LCA are
normally the two most common of the colonic bile acids in
humans (152). The 7-hydroxy group of CDCA can also by
epimerized (7-hydroxy to 7-hydroxy) to yield UDCA,
which compared with other dihydroxy bile acids is rela-
tively hydrophilic and has very distinct biological proper-
ties. However, UDCA is normally present at relatively low
levels since epimerization at C-7 is mediated by only a few
bacterial species and it is also rapidly metabolized by bac-
terial hydroxysteroid dehydrogenases to LCA, a reversible
reaction with 7-keto-LCA being an important intermediate.
Bile acids can also undergo epimerization at the C-3 hy-
droxyl group during transit through the intestine, with such
3-hydroxy bile acids being termed “iso” bile acids;
isoCDCA, isoDCA, and isoLCA are present in the colon but
upon reabsorption and recirculation to the liver, they un-
dergo re-epimerization to their 3-hydroxy counterparts
(169). The bacterial enzymes mediating alterations to bile
acid hydroxyl groups are less widely expressed than BSHs,
but their actions are also critically important in determining
their membrane permeability, cytotoxicity, and receptor se-
lectivity. Readers wishing to learn more detail of bile acid
metabolism and nomenclature are directed to previously
published reviews (172, 383).
B. Enterohepatic Cycling of Bile Acids
The enterohepatic circulation (EHC) of bile acids is an ex-
tremely complex and elegant process that includes their
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synthesis in the liver, storage in the gallbladder, transit
through the intestinal tract, bacterial metabolism, reab-
sorption from the small intestine and colon, transport via
the portal circulation to the liver, and reuptake into
hepatocytes (FIGURE 1). In the liver, recirculated bile ac-
ids can be further metabolized by hepatic enzymes and
reconjugated to glycine and taurine after which they are
then secreted into the bile and recirculated to the gall-
bladder for storage. Efficient enterohepatic cycling en-
sures that a relatively constant-sized pool of bile acids is
available to facilitate lipid digestion and absorption,
rather than de novo synthesis being required each time
food is ingested. The amount of bile acids in the EHC can
be calculated by isotope dilution (261) and in humans is
in the range of 2,000–3,000 mg, which is approximately
six times the daily synthesis rate (300–500 mg/day). Nor-
mally, the size of the circulating bile acid pool is kept
relatively constant with fecal loss being balanced by he-
patic synthesis.
After bile acids enter the small intestine, they perform their
classical functions in aiding the digestion and absorption of
fats. Absorption of bile acids themselves from the intestinal
lumen occurs by several mechanisms. Glycine-conjugated
dihydroxy bile acids (glyco-DCA and glyco-CDCA) are rel-
atively hydrophobic and can undergo passive absorption
from the duodenum when luminal contents are transiently
acidic. These glycine-dihydroxy bile acids can also be ab-
sorbed from the jejunum via organic anion transporting
polypeptide (OATP) transporters (144). Postprandial levels
of CDCA conjugates increase ahead of cholyl conjugates,
indicating the CDCA conjugates are more efficiently ab-
sorbed in the proximal small intestine (398).
Although reabsorption in the proximal small intestine con-
tributes to the EHC of bile acids, the most important reab-
sorptive process occurs in the terminal ileum, where epithe-
lial cells express the apical sodium-dependent bile acid
transporter, ASBT (also known as the ileal bile acid trans-
porter, IBAT). In contrast to other transporters involved in
the EHC (e.g., OST/OST, NTCP, BSEP) which can trans-
port non-bile acid molecules, ASBT transports only bile
acids and has a greater affinity for those that are conjugated
over those that are not. Thus it is ASBT which confers the
specificity of the EHC for bile acids (89, 91).
Following uptake by ASBT, bile acids traverse the cyto-
plasm of the epithelial cells bound to ileal bile acid binding
protein (IBABP) and exit the basolateral domains of the
enterocyte via the heterodimeric protein, OST/OST, a
facilitated diffusion transporter that is present throughout
the small intestine (89, 90). Once in the interstitium, it is
unclear how conjugated bile acids enter villus capillaries to
gain access to the portal circulation. However, as capillary
endothelial cells are fenestrated, similar to hepatic endothe-
lial cells, entry of bile acids into the capillary plexus likely
occurs by a passive process. Once in the portal venous
blood, bile acids are transported bound to albumin, with
dihydroxy conjugates binding more tightly (90%) than
conjugates of cholic acid (60–80%) (337).
Upon deconjugation in the terminal ileum and colon, bile
acids become more hydrophobic and are primarily reab-
sorbed by passive diffusion across the epithelium. Absorp-
tion of DCA is 20–50% of that formed (462), while that of
lithocholic acid is less, presumably because its hydropho-
bicity promotes binding to unabsorbed dietary constituents
Hepatocyte: synthesis, reuptake, secretion
Ileum:
Active transport
of conjugated
BA
Colon:
Microbial
metabolism of BA  
BSEP 
BAs 
NTCP 
SHP 
FGFR4/KLB 
FGF19 
CYP7A1
 
FXR 
FXR 
ASBT 
OSTα + OSTβ
IBABP 
FGF19 
SHP 
Small intestine:
digestion  
Biliary tree
Absorbed BAs
(95%)
Unabsorbed
BAs (5%)
Portal vein:
Recirculation of
reabsorbed BA
FIGURE 1. Enterohepatic circulation of bile acids. Bile acids
(BAs) are synthesized in the liver with the enzyme, CYP7A1,
being the initial step. They are transported from the liver by the
bile salt export pump (BSEP) and travel via the biliary tree to the
gallbladder for storage. Upon ingestion of a meal, bile acids are
ejected into the small intestine, where they facilitate lipid di-
gestion and absorption. In the ileum, active reuptake of conju-
gated bile acids occurs via the apical bile salt transporter
(ASBT), expressed in the brush border of terminal ileal epithe-
lial cells. In the cytoplasm, bile acids bind to ileal bile acid
binding protein (IBABP) and are transported from the ileal
enterocyte via the basolateral heterodimeric protein OST /.
Bile acids enter the portal venous circulation and return to the
liver, where reuptake takes place via the Na-taurocholate
polypeptide (NTCP). In both enterocytes and hepatocytes, BAs
bind to FXR in the nucleus, stimulating transcription of proteins
including SHP and FGF19. Approximately 5% of ileal BAs are
not absorbed and enter the colon where they are metabolized
into secondary bile acids by the microbiota, with some being
reabsorbed and recycled.
REGULATION OF INTESTINAL EPITHELIA BY BILE ACIDS
1985Physiol Rev • VOL 98 • OCTOBER 2018 • www.prv.org
Downloaded from www.physiology.org/journal/physrev at Univ of Szeged (160.114.106.153) on January 29, 2019.
(79).When these unconjugated bile acids return to the liver,
they are reconjugated with glycine or taurine and secreted
into canalicular bile. In some species, deoxycholic acid un-
dergoes 7-hydroxylation to form cholic acid which is then
conjugated with taurine or glycine. Additionally, in humans
but not in rodents, a major fraction of lithocholic acid is
esterified with sulfate after reconjugation. Such sulfolitho-
cholyl amidates are secreted into the bile but cannot be
absorbed from the small intestine, with the result that LCA
is rapidly eliminated from the body. Thus LCA constitutes
5% of biliary bile acids, with higher proportions being
associated with hepatotoxicity, at least in animals.
Hepatic uptake of bile acids remains constant during meals,
and under normal circumstances of feeding and fasting, it is
likely to remain far below its Vmax. Uptake of bile acids is
greatest in the periportal hepatocytes and is more efficient
for conjugated than unconjugated molecules (337). Conju-
gated bile acid uptake is mediated mostly by the sodium/
taurocholate cotransporting polypeptide (NTCP, gene
name SLC10A1), which has considerable homology to
ASBT, and like ASBT, uses the transepithelial sodium gra-
dient to drive uptake. After they have been taken up into the
liver, bile acids are then secreted into the bile via an ATP-
driven transporter, known as the bile salt export pump
(BSEP). This protein is present in the canalicular membrane
of hepatocytes and transports bile acids against a steep con-
centration gradient. The importance of NCTP and BSEP in
the EHC is underscored by congenital disorders in which
they are dysfunctional, with absence of NCTP causing
markedly elevated plasma levels of bile acids (468), and
inborn errors of BSEP being characterized by bile acid re-
tention, hepatocyte death, and inflammation (187).
Each stage of the EHC, from hepatic synthesis, to intestinal
reabsorption, and reuptake into hepatocytes, is intricately
regulated by complex pathways of cellular and molecular
communication along the gut-liver axis. Importantly, bile
acids themselves play amajor role in regulating this process,
primarily through their actions on farnesoid X receptor
(FXR) expressed in hepatocytes and epithelial cells lining
the intestinal lumen. FXR reversibly binds bile acids, with
CDCA being the most active natural agonist (273, 345).
When activated by bile acids, FXR forms a dimer with the
retinoic acid receptor (RXR) and binds to specific FXR-
responsive elements in target genes, several of which are
involved in bile acid metabolism and transport. In the liver,
a major FXR target gene that regulates CYP7A1 expression
is short heterodimer partner-1 (SHP). SHP itself does not
bind DNA but instead inhibits the activity of liver receptor
homolog 1 (LRH-1), thereby reducing CYP7A1 expression
and bile acid synthesis (140).
A number of other FXR-dependent pathways are also in-
volved in regulating bile acid synthesis and transport in the
liver and have been reviewed elsewhere (69, 88, 229) In
humans, ileal ASBT expression is downregulated by activa-
tion of FXR, whereas IBABP and the basolateral transport-
ers, OST and OST, are upregulated, effects that decrease
the concentration of bile acids within the ileal enterocyte
(125, 284, 519). However, the most prominent and best-
characterized of the FXR responsive genes in the ileum is
fibroblast growth factor 19 (FGF19), and its homolog
FGF15 in rodents. These are proteins of ~24 kDa that are
secreted from the basolateral aspect of ileal enterocytes into
the portal venous blood. FGF15/19 then travels to the liver
where it binds to FGF receptor 4 (FGFR4) and its co-recep-
tor, Klotho-beta, on hepatocytes to inhibit CYP7A1 via a
MAPK-dependent signaling mechanism (424). This pro-
vides an elegant system of negative-feedback regulation of
bile acid synthesis, whereby bile acid reabsorption in the
ileum signals through the gut-liver axis to inhibit de novo
synthesis in the liver. FGF19 levels peak in blood several
hours after a meal and are inversely related to those of the
bile acid precursor C4 (267), the plasma levels of which
increase in direct relationship to the rate of bile acid synthe-
sis. Under pathological conditions, such as those causing
bile acid diarrhea, defective production of FGF15/19 leads
to a loss of this negative-feedback loop, with increased syn-
thesis resulting in epithelial cells along the upper and lower
intestinal tract being exposed to considerably higher levels
of bile acids (482).
Other pathological conditions can also lead to disruptions
in the EHC with the consequence that epithelial cells, both
within and outside of the intestinal tract, become exposed
to bile acids. For example, conditions associated with mal-
absorption of bile acids in the terminal ileum (e.g., Crohn’s
disease) cause their increased delivery into the colon. On the
other hand, in gastroesophageal reflux disease (GERD), the
EHC leaks upwards with the result that cells of the esoph-
agus and airways can become exposed to bile acids. Simi-
larly, common channel obstruction can cause bile acids to
enter the pancreas where they come into contact with the
epithelial cells lining the ducts and acini. Not surprisingly,
such conditions can dramatically alter the physiology of
these cells leading to the onset of disease.
III. EPITHELIAL CELL PHYSIOLOGY
Before we consider how they are regulated by bile acids, in
this section we review the basic functions and physiological
characteristics of intestinal epithelial cells. These cells, lin-
ing the surfaces of the entire intestinal tract and its acces-
sory organs, are exposed to constantly changing luminal
conditions and must have the capacity to adapt appropri-
ately. For example, in the intestine, the epithelium must be
able to evoke rapid responses upon ingestion of ameal. This
is achieved through the release of hormonal messengers,
secretion of digestive enzymes, and expression of transport
proteins that enable the uptake of fluid and nutrients from
the lumen. At the same time, the epithelia must also act as
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barriers that protect against the entry of harmful sub-
stances, whether they originate endogenously (e.g., gastric
acid, digestive enzymes, bile acids) or are ingested (e.g.,
bacteria, viruses, fungi, and their toxins). Given the widely
diverse functions of different intestinal regions and the dif-
ferent stimuli to which they are exposed, it is not surprising
that epithelial cells express regional and organ-specific
characteristics. However, throughout the intestine, epithe-
lial cells also have common characteristics that are essential
to their fundamental barrier and transport functions (FIG-
URE 2).
Epithelial cells in the intestinal tract originate from stem
cells located near the base of crypts. Stem cells give rise to
progenitor cells which, in turn, develop into one of the four
main types of epithelial cell; enterocytes, goblet cells, and
enteroendocrine cells migrate upwards from the stem cell
niche, while Paneth cells migrate downwards towards the
crypt base. Enterocytes are the most common of the intes-
tinal epithelial cells and are responsible for the surface hy-
drolysis and uptake of nutrients, absorption and secretion
of electrolytes and fluids, and the conservation of bile acids.
Goblet cells secrete mucus which promotes intestinal bar-
rier function, protecting against pathogen invasion and
physical damage due to peristalsis (288). Paneth cells se-
crete antibacterial peptides, most notably defensins and ly-
sozyme, which are important in intestinal defense against
bacterial infection. Paneth cells are also important in main-
tenance of the stem cell niche (75). Enteroendocrine cells
serve to “taste” the luminal contents and release hormones
and neurotransmitters that enable coordination of both lo-
cal and systemic responses to the presence of nutrients in the
intestine (270). A subset of enteroendocrine cells, the L
cells, can also sense bile acids in the gut lumen through their
expression of TGR5 and FXR, with signals from these re-
ceptors regulating the expression of the incretin hormone,
glucagon-like peptide-1 (GLP-1). Such actions link changes
in luminal bile acids to changes in our metabolism and
energy expenditure and are the basis for a great deal of
ongoing research into the potential for targeting bile acids
in treatment of metabolic diseases, such as diabetes and
obesity. This exciting and complex area of research is be-
yond the scope of the current review, and we direct the
reader to several recent publications for further information
(47, 146, 344, 431, 450, 464).
The ability of epithelial cells to form barriers and to vecto-
rially transport nutrients, fluid, and ions is dependent on
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FIGURE 2. General characteristics and functions of intestinal epithelial cells. The primary functions of
epithelial cells throughout the intestinal tract are to transport nutrients, electrolytes, digestive enzymes, and
fluid to and from the lumen, while at the same time acting as a protective barrier to prevent the entry of harmful
pathogens and toxins. Transport of substances between the luminal contents and the body is enabled by two
specific epithelial properties. First, the polarized expression of transport proteins on the apical and basolateral
membranes allows for the vectorial movement of solutes in the luminal or mucosal direction. Second, the
capacity of epithelial cells to form ion-selective tight junctions (TJs) with one another enables them to create
selectively permeable monolayers across which electrical and osmotic gradients can be established. Barrier
function is comprised of the physical barrier posed by the epithelial cells themselves and their associated TJs
along with a number of factors secreted across the apical membrane, including mucus, antimicrobial peptides
(AMPs), acid-neutralizing HCO3
, and fluid. Secretion of cytokines and chemokines across the basolateral
membrane into the mucosa regulates the recruitment of innate immune cells that augment the barrier
properties of the epithelium.
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their ability to form tight junctions and to undergo func-
tional polarization. Functional polarity refers to the ability
of epithelial cells to differentially express proteins on their
apical and basolateral surfaces. Such differentially ex-
pressed proteins include the transport proteins that facili-
tate the vectorial movement of substances across the epithe-
lial layer and the receptors that are involved in their regu-
lation. Tight junctions are an essential feature in the
development andmaintenance of functional polarity, divid-
ing the membrane into distinct apical and basolateral do-
mains and providing a focal point from which membrane
proteins are sorted to each domain (278, 491). At the ex-
tracellular side, tight junctions make contact with each
other through homotypic binding of their structural trans-
membrane components, occludin, claudins, and junctional
adhesion molecule. Tight junctions form paracelluar pores
through which solutes and water can flow, the permeability
of which is determined primarily by the particular claudins
expressed within the junctions (237, 456). Tight junctions
are not static but open and close in response to many en-
dogenous and exogenous stimuli, thereby controlling the
paracellular passage of fluid and solutes to and from the
lumen.
A. Epithelial Fluid and Electrolyte Transport
One of the most important functions of epithelial cells is to
regulate water movement across the various surfaces of the
intestinal tract and its accessory organs. From beginning to
end, water secretion is necessary for a number of vital pro-
cesses in the intestine, including providing a liquid medium
for digestion and diffusion of enzymes and nutrients, for
lubricating and protecting the mucosal surface, and for di-
luting potentially harmful substances, for example, diges-
tive enzymes in the pancreatic ductules. On the other hand,
the ability of epithelial cells to absorb water is also critical
since this is required not only to prevent dehydration but
also in processes that require concentration of the luminal
contents, for example, in the formation of bile. The volumes
of fluid that are moved across intestinal epithelial surfaces
on a daily basis are great. Each day ~9 liters of fluid enters
the proximal small intestine, comprised of ~2 liters of in-
gested fluid and 7 liters of digestive secretions arising from
the stomach, duodenum, pancreas, and liver. It is remark-
able that of this fluid load,200 ml are normally lost in the
feces, illustrating the extraordinary efficiency with which
the intestine handles fluid.
Fluid movement across epithelial cells occurs passively in
response to the osmotic gradients established by active sol-
ute transport. In turn, solute transport is governed by the
activity of various transport proteins that are arranged into
pathways specific to the location and function of the par-
ticular epithelial cell. For example, the organization of
transport proteins in pancreatic and biliary ductal cells,
which secrete aHCO3
-rich fluid, is quite distinct from that
of the surface cells of the colon, which avidly absorb Na.
1. Secretory pathways
In the intestine, fluid secretion occurs predominantly from
the crypts and is driven by electrogenic Cl secretion. The
molecular process of Cl secretion involves the concerted
activity of several basolateral transport proteins, including
Na-K-ATPase pumps, the Na/K/2Cl cotransporter
NKCC1, and the K channels KCNQ1 and KCNN4 (34).
Together the activity of these transporters serves to elevate
intracellular levels of Cl above its electrochemical equilib-
rium, creating a gradient for its exit when channels in the
apical membrane open. The cystic fibrosis transmembrane
conductance regulator (CFTR), a Cl channel that opens in
response to phosphorylation by cAMP-dependent protein
kinase A, is the primary exit pathway for Cl in intestinal
epithelia. A Ca2-dependent Cl channel, TMEM16A, is
also expressed (319), although its contribution to transepi-
thelial water transport is not well defined.
While Cl secretion is the main driving force for fluid se-
cretion in the distal intestine, HCO3
 secretion predomi-
nates in more proximal regions, such as the duodenum.
Here, HCO3
 secretion serves to neutralize acid entering
the small intestine from the stomach. HCO3
 secretion oc-
curs either through an electrogenic pathway which involves
its exit across the apical membrane through CFTR or an
electroneutral pathway involving the Cl/HCO3
 exchang-
ers DRA and PAT-1 (405).
2. Absorptive pathways
In the ileum and colon, fluid absorption normally predom-
inates and is driven by cation absorption, most notably that
of Na, through three main processes. In the small intes-
tine, Na-nutrient cotransporters, including SGLT-1 and
Pept1, are primarily responsible for fluid absorption after
eating a meal (504). Electroneutral Na absorption, a pro-
cess mediated by coordinated activity of the sodium-hydro-
gen exchangers, NHE3 and NHE2, and the chloride bicar-
bonate exchangers, DRA and PAT1 (211), occurs through-
out the small and large intestine and is responsible for fluid
absorption in interdigestive periods. Electrogenic Na ab-
sorption occurs in the colon through Na channels known
as ENaC (176). The energy for each of these processes is
derived from the activity of basolateral Na-K-ATPase
pumps which maintains intracellular Na at low levels,
thereby facilitating its influx through apically expressed
SGLT1, NHE3, and ENaC.
B. Epithelial Barrier Function
While they are carrying out their roles in fluid, nutrient, and
electrolyte transport, intestinal epithelia must also form a
barrier to prevent mucosal damage from harmful luminal
contents, such as acid, proteases, and invading pathogens.
There are twomain components to this physical barrier: the
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epithelial cells themselves and the tight junctions which
hold them together. Normally, there is a tightly regulated
balance between epithelial proliferation and programmed
cell death by apoptosis, ensuring the integrity of the barrier.
However, should this balance become dysregulated, for ex-
ample, as a consequence of increased apoptosis in the set-
ting of inflammation, then barrier function can become
compromised allowing access of the luminal contents to the
mucosa. The permeability of tight junctions can also be
affected in disease conditions, where alterations in the phos-
phorylation or expression of tight junction proteins can
lead to opening of the paracellular pores.
In addition to the physical barrier posed by epithelial cells
themselves, there are several other innate factors that are
crucial in augmenting barrier function. These include water
secretion, whether it is driven by HCO3
 or Cl, mucus
secretion from goblet cells, defensin secretion from Paneth
cells, and secretory IgA secretion. Together these compo-
nents create a protective layer overlying the epithelium
which protects against erosion and prevents entry of patho-
gens and their toxins. Furthermore, epithelial cells also pro-
duce an array of cytokines and chemokines, conferring
themwith the ability to recruit immune cells, such as mono-
cytes and neutrophils, to enhance barrier function in times
of infection or inflammation.
C. Regulation of Epithelial Transport and
Barrier Function
To function effectively, intestinal epithelia must be able to
adapt to the constantly changing environment of the lumen.
The activity and expression of proteins involved in mainte-
nance of barrier and transport function are closely regu-
lated by integrated signals arising from the luminal con-
tents, the enteric nervous system, the mucosal immune
system, blood-borne hormones, the resident microbiota,
and the epithelium itself (34, 87, 121, 145, 219, 412,
502). In the short term, rapid changes in epithelial func-
tion occur by posttranslational modifications or altered
cell surface trafficking of proteins that constitute tight
junctions and transport pathways. In the longer term, tran-
scriptional mechanisms regulate the cellular expression of
these proteins. Often, changes in junctional and transport
proteins occur simultaneously, enabling the coordination of
epithelial permeability to fluid, nutrient, and electrolyte
transport.
IV. BILE ACIDS AND EPITHELIAL
SIGNALING
Whether in the small or large intestine, the gallbladder, or
the liver, epithelial cells of the lower intestine and biliary
tract are constantly exposed to bile acids. However, the
levels and types of bile acids to which they are exposed vary
considerably from tissue to tissue. Furthermore, pathologi-
cal conditions, notably cholestasis or GERD, can result in
epithelial cells of the pancreas, upper gastrointestinal tract,
or the airways coming into contact with bile acids.With this
in mind, it is perhaps not surprising that bile acids have
emerged as important regulators of epithelial physiology
and pathophysiology and, indeed, studies from more than
100 yr ago were already reporting how bile acids contribute
to the pathogenesis of diseases, such as gastric ulcers and
pancreatitis (122, 301, 335). Since then bile acids have been
found to have the capacity to modulate many aspects of
epithelial function and to play important roles in disease
pathogenesis. With the discovery of nuclear and cell surface
receptors for bile acids, the past decade has perhaps seen the
greatest advances in our understanding of how bile acids
exert their effects on epithelial cells, and with these ad-
vances, we have begun to truly appreciate the critical roles
that they play in intestinal homeostasis.
A. Epithelial Sensing of Bile Acids
Although bile acids have been known for many decades to
alter levels of intracellular second messengers and activate
signaling cascades, our knowledge of how they initially in-
teract with epithelial cells to trigger such responses has only
slowly evolved. However, at the turn of the millennium, the
discovery of the first “dedicated” bile acid receptors stimu-
lated an exciting new era of research in the field. Our un-
derstanding of how these molecules exert their physiologi-
cal and pathological effects has since been rapidly growing.
1. TGR5: the cell surface bile acid receptor
TGR5, a member of the G protein-coupled receptor
(GPCR) superfamily, was discovered as a plasma mem-
brane receptor for bile acids in 2002 (213, 282). The coding
sequence of the TGR5 gene contains 993 base pairs, encod-
ing 330 amino acids with the 7 putative transmembrane
domains characteristic of GPCRs (213). In humans, the
TGR5 gene is located on chromosome 2q35, and mapping
of TGR5 mRNA expression shows that it is widely distrib-
uted, being present in the immune system, adipocytes, mus-
cle, and endocrine organs (213). TGR5 is expressed on
enteric nerves, innate immune cells, and epithelial cells
throughout the intestinal and biliary tracts (47, 173, 220,
221, 234, 488). TGR5 is characterized as a GsPCR, and its
activation stimulates increases in levels of intracellular
cAMP and activation of protein kinase A, leading to phos-
phorylation of target proteins. Activated effector proteins
can then alter cellular function either in the short term, or
more chronically, through regulating the activity of tran-
scription factors, such as cAMP response element binding
protein (CREBP) or C/EBP (213, 322, 363). TGR5 was
first recognized for its roles in energy homeostasis, through
its actions on energy expenditure in brown adipose tissue
and its enhancement of insulin sensitivity, thereby improv-
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ing glucose metabolism (212, 490). Based on such actions,
TGR5 is currently receiving a great deal of research interest
as a new target to treat liver, cardiovascular, and metabolic
diseases (108, 238, 364, 370, 397). However, given its
widespread expression throughout the body, consequences
of TGR5 activation are now known to be much broader
(50). In particular, TGR5 receptors on enteric neurons are
now known to be important in regulation of intestinal mo-
tility (8), while receptors expressed on innate immune cells
appear to dampen inflammatory responses (181, 291). The
most powerful known endogenous agonists of TGR5 are
bile acids with the rank order of potency of lithocholic acid
 deoxycholic acid chenodeoxycholic acid cholic acid
(213). Taurine-conjugated bile acids are more potent than
unconjugated bile acids, which, in turn are more potent
than glycine-conjugated bile acids. Semi-synthetic agonists
of TGR5 have also been developed, the most potent of
which, to date, is 6-ethyl-23(S)-methyl cholic acid (S-
EMCA; INT-777), synthesized by Pellicciari et al. (354).
Another modified bile acid derivative, INT-767, a C24 bile
alcohol sulfate, activates both TGR5 and FXR (384).
2. Nuclear bile acid receptors
Although first discovered as an “orphan” receptor that is
weakly responsive to farnesoids (124), FXR was subse-
quently identified as a primary nuclear receptor for bile
acids in 1999 (273, 484). FXR is one of the 48 members of
the nuclear receptor superfamily and contains a DNA bind-
ing domain (DBD), a ligand binding domain (LBD), and
additional activation domains. In its ligand-free state, FXR
exists as a heterodimer with RXR and is bound to specific
FXR response elements (FXREs) on target genes (206).
Upon ligand binding, FXR undergoes a conformational
change which induces the release of co-repressor proteins
and the recruitment of co-activators, such as SRC-1,
PGC1, and PRMT-1 (224). Although two genes encoding
FXR, FXR and FXR, exist, FXR is not functional in
humans, while FXR exists as four isoforms (FXR1–4)
that can differentially drive the activation of FXREs on
different genes (175, 521). FXR is expressed in tissues and
organs throughout the body but is at particularly high levels
in tissues involved in regulating bile acid homeostasis, such
as the liver, intestine, and kidneys (41, 124, 175, 273, 360).
FXR is also expressed on epithelial cells of the small intes-
tine, stomach, colon, esophagus, biliary tree, and pancreas
(92, 162, 201, 234, 257). It is also found on enteroendo-
crine L cells (449). FXR was first recognized as being a
critical contributor to intestinal/hepatic crosstalk in regula-
tion of bile acid biosynthesis and transport (266, 273) but,
similar to TGR5, was soon found to be also important in
controlling metabolic homeostasis (55, 210, 419). Cur-
rently, FXR is receiving a great deal of interest for its po-
tential in treating liver diseases, such as non-alcoholic ste-
atohepatitis (NASH) and primary biliary cirrhosis (PBC),
and metabolic disorders, particularly diabetes and obesity.
These important applications of FXR agonists have been
reviewed extensively elsewhere (3, 257, 326, 370). The
structure-activity relationship for bile acids in activating
FXR differs considerably from that of TGR5 with a rank
order of potency of: CDCA  DCA  LCA  CA (484).
Several specific steroidal and nonsteroidal FXR agonists
have been developed, including GW4064, obeticholic acid
(OCA), fexaramine, and GSK2324 (408). These agonists
have proved to be important tools for developing our un-
derstanding of the roles of FXR in health and disease. To
date, the most clinically advanced of these agonists is OCA,
which is the first specific FXR agonist to receive Food and
Drug Administration (FDA) approval for use in humans
(166).
In addition to FXR, there are other nuclear receptors that
can be activated by bile acids. For example, the pregnane X
receptor (PXR) is highly expressed in the liver and intestine
and is best known for its roles in detoxification of drugs and
xenobiotics (57). However, PXR is a very promiscuous re-
ceptor and can also be activated by numerous endogenous
substances, including bile acids. It was first identified as a
receptor for LCA in 2001, with its activation (in mice) in-
ducing the expression of proteins required for its detoxifi-
cation (by additional hydroxylation or sulfation), trans-
port, and excretion of this toxic bile acid from the body
(432). While PXR is activated by LCA, its oxidized metab-
olite, 3-keto-cholanoic acid, and also by UDCA, it is only
weakly responsive to CDCA, DCA, CA, and conjugated
bile acids, making its sensitivity to bile acids quite distinct
from that of FXR (401). Recent years have seen consider-
able advances in our understanding of the physiology and
pathophysiology of PXR, and it is now known that in ad-
dition to its detoxifying roles it also exerts potent cytopro-
tective and anti-inflammatory effects on intestinal epithelial
cells (65, 296, 445, 524).
The vitamin D receptor (VDR) is another nuclear receptor
that is widely expressed throughout the body in tissues such
as bone, kidney, intestine, and innate immune cells. VDR
controls numerous physiological processes, including bone
and calcium metabolism, inflammatory responses, and cell
growth, survival, and differentiation (71, 258, 391). While
the classical endogenous ligand of VDR is 1,25-dihy-
droxyvitamin D3, studies have shown that it can also be
activated by LCA and that, similar to PXR, it regulates
genes involved in metabolism and transport of that bile acid
(272). Furthermore, VDR activation stimulates ileal epithe-
lial secretion of FGF15, leading to subsequent repression of
hepatic CYP7A1. This suggests that the VDR plays a com-
plementary role to the FXR in regulating the synthesis and
EHC of bile acids (153). Meanwhile, other studies have
shown that, similar to PXR and FXR, activation of VDR
exerts cytoprotective and anti-inflammatory actions in the
intestine (51, 258).
HEGYI ET AL.
1990 Physiol Rev • VOL 98 • OCTOBER 2018 • www.prv.org
Downloaded from www.physiology.org/journal/physrev at Univ of Szeged (160.114.106.153) on January 29, 2019.
Finally, the glucocorticoid receptor (GR) is another nuclear
receptor that has the capacity to mediate responses to bile
acids, particularly UDCA. In several experimental systems,
UDCA has been shown to induce nuclear translocation of
the GR and activation of GR-dependent genes that modu-
late immune responses (441, 443, 496). Interestingly, the
effects of UDCA appear to be mediated through its binding
to a region of the GR LBD that is distinct to that bound by
the classical GR agonist dexamethasone, in turn leading to
the regulation of a distinct subset of GR-dependent genes
(304).
3. Receptor crosstalk
In addition to directly binding to and activating their cog-
nate receptors, bile acids can also induce cellular responses
by recruiting “non-bile acid” receptors. For example, recent
studies have shown that TGR5 can transactivate the epider-
mal growth factor receptor (EGFr), thereby enabling the
recruitment of tyrosine kinase-dependent signaling path-
ways to regulate cell growth (190, 380, 511). Studies by
Cheng and Raufman (66) have demonstrated that taurine
and glycine conjugates of LCA and DCA can also induce
EGFr transactivation, but in this case, through their actions
as partial agonists of the muscarinic M3 receptor. Further
studies suggest that such bile acid-induced GPCR/EGFr
crosstalk is mediated by metalloprotease-induced shedding
of EGFr ligands from the cell membrane (14, 67, 297, 317,
497) and inhibition of EGFr degradation (56). However,
although it is clear that EGFr activation plays an important
role in mediating epithelial responses to GPCRs activated
by bile acids, such responses are also likely to be tempered
by their activation of FXR, which has been shown to inhibit
EGFr-dependent signaling in intestinal epithelial cells (105,
357). Studies from mammary epithelial cells indicate that
FXR activation may also inhibit EGFr-dependent signaling
by downregulating expression of other members of the
ErbB receptor family with which it heterodimerizes (135).
Interestingly, GR and VDR activation have also both been
shown to be coupled to inhibition of EGFr signaling and
expression, suggesting that bile acids may also have the
capacity to influence growth factor-dependent signaling
through these pathways (290, 382). Understanding how
such complex mechanisms of crosstalk between bile acid
and growth factor receptors ultimately impact intestinal
epithelial physiology should be an important area of re-
search focus in the coming years.
4. Membrane perturbations
Finally, in addition to activating specific cell surface GPCRs
and intracellular nuclear receptors, bile acids can also initi-
ate signaling in epithelial cells by causing perturbations in
the plasma membrane. Studies have shown that treatment
of colonic epithelial cells with hydrophobic bile acids cause
a redistribution of membrane cholesterol and phospholip-
ids, leading to alterations in caveolin expression and mem-
brane fluidity within distinct microdomains (189). Interest-
ingly, such effects also bring about transactivation of the
EGFr but, in contrast to TGR5- and M3R-mediated re-
sponses, they appear to do so independently of EGFr ligand
shedding (5, 189). While further investigation is required, it is
tempting to speculate that such distinct mechanisms of EGFr
transactivation would lead to different patterns of receptor
phosphorylation, differential recruitment of downstream ef-
fector pathways, and ultimately, different cellular responses to
different bile acids.
B. Intracellular Signaling by Bile Acids
Bile acids can alter epithelial function both in the short and
long term. Rapid responses to bile acids involve changes in
the levels of intracellular second messengers, such as Ca2,
cAMP, and reactive oxygen species subsequent to activa-
tion of cell surface receptors or induction of membrane
perturbations. These second messengers can then alter cell
physiology either through direct interactions with effector
proteins or indirectly through the activation of signaling
cascades that alter the phosphorylation and activity of
downstream effectors. Kinase cascades commonly reported
to be involved in mediating the actions of bile acids include
protein kinase C (PKC), protein kinase A (PKA), ERK, JNK
and p38 mitogen-activated protein kinases (MAPKs), to
name but a few (19, 139, 250, 305, 394, 438). The lipid
kinase phosphatidylinositol 3-kinase (PI3K) has also been
shown to be an important mediator of bile acid actions in
many different systems (19, 425). Another type of post-
translational modification that can rapidly alter cell func-
tion in response to bile acids is ubiquitination, leading to
proteosomal degradation of effector proteins (13, 306).
Degradation of proteins can also occur by the process of
autophagy, and recent studies suggest that bile acids are
also important regulators of this process in hepatocytes,
enterocytes, and pancreatic epithelial cells (45, 275, 351,
508). Rapid alterations in the trafficking of proteins to and
from the cell surface can also occur in response to bile acids
through regulating their internalization by endocytosis
(202, 400).More long-term changes in epithelial phenotype
can be brought about through altering the expression of
proteins that contribute to barrier and transport function.
Such changes can occur in response to the activation of
transcription factors (e.g., NFB, AP-1, CREB) down-
stream of intracellular second messengers, or by activation
of nuclear receptors (e.g., FXR, PXR, VDR). Bile acids can
also alter the expression of effector proteins through regu-
lating miRNA production (64, 120, 507), or by epigenetic
mechanisms, involving DNA methylation or histone
deacetylation (228, 262). A summary of bile acid-induced
epithelial signaling mechanisms is shown in FIGURE 3.
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C. Bile Acids and the Microbiota
One of the primary determinants of the bioactivity and
bioavailability of bile acids in the intestine is their metabo-
lism by residentmicrobes The colon is home to a population
of trillions of bacteria, comprised of hundreds of different
species, many of which have the capacity to metabolize bile
acids. Normally, through deconjugation and dehydroxyla-
tion, the colonic microbiome converts conjugated bile ac-
ids, which have failed to be absorbed via the ASBT in the
small intestine, into more hydrophobic molecules. Since
there are no reports of ASBT being expressed on the apical
membrane of colonic epithelial cells, increased hydropho-
bicity and decreased ionization enables bile acid reabsorp-
tion by passive diffusion across the cell membrane.
The most rate-limiting step in bacterial metabolism of bile
acids is deconjugation of glycine or taurine by the action of
bile salt hydrolases (BSH). This reaction dramatically
changes the physicochemical properties of the bile acids,
making them more lipophilic and partially protonated and
thereby enabling further metabolism by dehydroxylases
and epimerases (200, 256). The past two decades have seen
enormous advances in our understanding of how the micro-
biome influences human health, not only in the intestine
(348), but also through its roles in regulating energy expen-
diture, metabolism, and cardiovascular function (46, 154,
503). By way of the gut-brain axis, the microbiome is now
becoming recognized as an important regulator of higher
central functions, including emotional state and appetite (6,
82, 117). It even regulates our circadian rhythms (199,
447).
The microbiome is highly dynamic and its composition de-
pends on many factors, including diet, environment, age,
fitness level, and psychological state, to name but a few (73,
264, 269, 333). It is also clear that dramatic changes in the
microbiome can occur in many disease states, and being at
the dividing line between the human and microbial worlds,
the epithelium has a critical role to play in mediating the
effects of such changes. Understanding how bacteria and
epithelial cells communicate with one another under nor-
mal and disease states is a critically important area of re-
search that is advancing rapidly. Bile acids clearly have an
important role to play in this communication network,
since changes in the microbiome lead to changes in bile acid
metabolism and, consequently, changes in the hydropho-
bicity/hydrophilicity ratio of the colonic bile acid pool (107,
205). Thus the precise levels of different bile acids in the
colon, i.e., the “colonic bile acid signature” is determined
by the makeup of the microbiota. In turn, each individual’s
bile acid signature determines what contributions TGR5,
FXR, VDR, PXR, M3R, GR, EGFr, and membrane disrup-
tions make in setting the overall tone of epithelial function
at any given time. A summary of how microbiota/bile acid
interactions impact on intestinal physiology in health and
disease is shown in FIGURE 4.
V. BILE ACIDS AND EPITHELIAL
FUNCTION
As discussed above, the two primary functions of intestinal
epithelial cells are to transport fluid electrolytes and nutri-
ents to and from the luminal contents and to act as a barrier
to prevent the entry of harmful substances from the intesti-
nal lumen to the mucosa. In their capacity as signaling mol-
ecules, bile acids play important roles in regulating both of
these aspects of epithelial function.
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FIGURE 3. Intracellular signaling in response to bile acids.
Bile acids induce acute responses (solid black arrows) in
epithelial cells through the activation of multiple receptor
types on the cell surface or through induction of membrane
perturbations. This leads to the generation of numerous
intracellular second messengers and the activation of signal-
ing cascades. Such signaling pathways can also lead to more
long-term changes in cellular function through the activation
of transcription factors and regulation of gene transcription
(dashed red arrows). Changes in gene transcription and
protein expression can also be brought about by the activa-
tion of several nuclear receptors, including farnesoid X re-
ceptor (FXR), pregnane X receptor (PXR), and vitamin D
receptor (VDR).
HEGYI ET AL.
1992 Physiol Rev • VOL 98 • OCTOBER 2018 • www.prv.org
Downloaded from www.physiology.org/journal/physrev at Univ of Szeged (160.114.106.153) on January 29, 2019.
A. Bile Acids in Regulation of Epithelial Fluid
and Electrolyte Transport
There has long been an association between bile acids and
intestinal fluid homeostasis. The first reports of the bile acid
binding resin cholestyramine being useful in treating diar-
rhea were published in the late 1960s (171, 387), and soon
afterwards a landmark study by Mekhjian et al. (295) di-
rectly demonstrated that instillation of bile acids at high
concentrations into the colons of healthy volunteers in-
duced fluid secretion. Subsequent studies in animal models
and cultured epithelial cell lines have revealed that the ef-
fects of bile acids on luminal fluid accumulation are due to
both inhibition of Na absorption and stimulation of Cl
secretion (40, 141, 294, 395). Although there can be quite a
degree of variation in their concentration dependence in
different models, it is clear that in most species, including
humans, only pathophysiologically high levels of bile acids
induce colonic fluid secretion. There is also a marked struc-
tural specificity for bile acids in exerting their actions, with
only the dihydroxy bile acids, CDCA and DCA, having
prosecretory effects (141, 217, 444). UDCA, the 7-OH
epimer of CDCA, is a notable exception in that it has been
shown to be devoid of prosecretory activity and, in fact, has
antisecretory actions (130, 223). Conjugation to glycine or
taurine is also an important factor in determining bile acid
actions on intestinal fluid transport. Since colonic epithelial
cells do not express apical transporters for bile acids, they
must first be deconjugated, to become more lipophilic and
partially protonated before they can passively cross the cell
membrane. However, if levels of luminal conjugated bile
acids increase sufficiently, loss of tight junction integrity
occurs, allowing bile acids to gain access to the basolateral
side where they can then be transported into the cell to exert
their effects (102, 217). Thus the colonic microbiome,
through its deconjugating, dehydroxylating, and epimeriz-
ing activities, is a crucial regulator of intestinal transport
responses to bile acids. While the physiological basis for
such cathartic actions of bile acids in the colon is still not
certain, it is thought they have likely evolved as an innate
defense mechanism to protect the mucosa at times when
colonic delivery of bile acids is abnormally high. Under such
conditions, bile acid-induced secretion dilutes colonic con-
tent and causes rapid elimination from the body, thus pre-
venting damage to the epithelial barrier.
The molecular mechanisms by which intestinal epithelial
transport function is altered by bile acids are still not fully
elucidated. However, in vitro studies in cell culture models
clearly show that they can exert their effects, at least in part,
through direct actions at the epithelium itself (101, 102,
217). Such direct effects of bile acids are mediated primarily
by elevations in intracellular Ca2, leading to activation of
basolateral KCNN4 channels, thereby creating the electri-
cal driving force for Cl secretion into the lumen. Such
Ca2-dependent prosecretory effects of bile acids have also
been reported in colonic tissues from animal models (286,
311). Studies on isolated colonic epithelial cells have shown
that bile acid-induced increases in intracellular Ca2 also
inhibit the activity of Na/H and Cl/HCO3
 exchangers
in the apical membrane of surface cells. In vivo, such an
effect would result in reduced salt and water absorption
from the lumen (11, 339). Recent studies in rats also suggest
that changes in epithelial expression of aquaporins occur
upon exposure to bile acids, although the contribution that
these channels make to intestinal fluid secretion is still un-
known (512).
While it is clear that elevations in intracellular Ca2 are
important in mediating bile acid actions, the upstream
mechanisms involved have yet to be elucidated. The strict
structure-activity relationship for bile acids in regulating
epithelial transport function suggests that a receptor may be
involved, but if this is so, its identity has yet to be revealed.
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FIGURE 4. Bile acid/microbial interactions in regula-
tion of intestinal physiology and pathophysiology. Environ-
mental and genetic factors contribute to determining the
nature of the microbial fingerprint that exists within the
intestinal lumen which, in turn, determines the makeup of
our intestinal bile acid signatures. Luminal bile acids reg-
ulate many different aspects of mucosal physiology, from
epithelial transport and barrier function to immune cell
and neuronal activation in the lamina propria. Bile acids
also play an important feedback role in shaping the mi-
crobial fingerprint. Dysregulation of microbial/bile acid
interactions can negatively impact mucosal function, con-
tributing to the onset of intestinal and metabolic disor-
ders (red arrows). In turn, disease progression can also
impact the intestinal flora, making it difficult to determine
whether changes in the microbial fingerprints and bile
acid signatures are a cause or consequence of disease.
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Our own studies suggest that the cell surface bile acid re-
ceptor TGR5 is not involved since, even though the receptor
is expressed on colonic epithelial cells, its activation with
the TGR5 specific ligand INT-777 inhibits, rather than
stimulates, Cl secretion in rat colonic tissue (488). Mean-
while, the rapidity with which bile acids induce epithelial
secretion (i.e., within seconds) rules out a role for nuclear
receptors. An alternative possibility to the involvement of a
specific receptor could be that hydrophobic bile acids cause
membrane perturbations, either at the plasmamembrane or
within intracellular organelles, such as mitochondria and
the ER, leading to the emptying of intracellular Ca2 stores
and increased influx from the extracellular milieu (255,
453).
In addition to their direct effects on epithelial cells, bile
acids can also alter intestinal fluid and electrolyte transport
through indirect mechanisms. In an important series of
studies carried out by Lundgren and co-workers at the Uni-
versity of Gothenburg, the involvement of intrinsic neural
reflexes in bile acid-induced fluid secretion in the small in-
testine was defined (208, 209). Subsequent studies revealed
that this reflex arc is initiated by enterochromaffin cells
which, in the presence of high luminal bile acid levels, re-
lease 5-HT to activate intrinsic afferent neurons (358). The
efferent arm of the reflex arc appears to bemediated by both
cholinergic and noncholinergic, nonadrenergic nerves that
release their neurotransmitters into the neuroepithelial
junction.
In addition to recruitment of the ENS, bile acids can also
stimulate intestinal secretion through the activation of im-
mune cells present in the lamina propria. For example, in
guinea pig colon, CDCA-induced secretory responses are
mediated, at least in part, by activation of mast cells and the
release of histamine, which then acts at epithelial H1 recep-
tors to induce secretion (130). Other mediators released
from activated mast cells, such as adenosine and prosta-
glandins, are also likely to be involved, although this re-
mains to be investigated. It should also be kept in mind that
mast cells and nerves exist in close apposition to each other
within the intestinal mucosa and engage in bidirectional
communication (94). Such neuroimmune interactions are
also likely to be important in regulating the full expression
of bile acid-induced intestinal transport responses.
While most studies to date have focused on how bile acids
acutely induce fluid and electrolyte secretion when they are
present at high levels in the colon, in more recent studies we
have begun to address possible roles they may play under
more physiological circumstances. It was found that
chronic exposure of isolated epithelial cells or rat colonic
tissue to relatively low DCA concentrations (10–200 M),
which by themselves do not induce secretion, inhibited sub-
sequent responses to both Ca2 and cAMP-dependent
secretagogues. This effect was slow in onset and was not
associated with alterations in secretagogue-induced in-
creases in intracellular second messengers (215). In subse-
quent studies it was found that such anti-secretory actions
are likely mediated by the nuclear bile acid receptor FXR,
since agonists of this receptor mimicked the antisecretory
actions of DCA and CDCA in cultured epithelial cells and
ex vivo sections of mouse colon. Actions downstream of
FXR activation appear to involve inhibition of the activity
at least two key components of the Cl secretory pathway,
apical CFTR channels and basolateral Na-K-ATPase
pumps (313). It was proposed that such antisecretory ac-
tions of bile acids may serve a physiological role by damp-
ening basal fluid secretion and thereby promoting the nor-
mal absorptive function of the colon. Such dual actions of
bile acids in acutely promoting and chronically inhibiting
fluid secretion at high and low levels, respectively, suggests
that they may have a role as colonic “osmosensors” that
serve to dynamically regulate luminal fluid levels. A sum-
mary of our current understanding of how bile acids regu-
late colonic secretion under normal and pathological cir-
cumstances is depicted in FIGURE 5.
B. Bile Acids in Regulation of Epithelial
Barrier Function
The intestinal epithelial barrier is comprised of the physical
barrier posed by the epithelial cells themselves, augmented
by a number of secreted factors, including antimicrobial
peptides, mucus, cytokines, and immunoglobulins. This
barrier is by no means static but is in a constant state of flux
as the cells which comprise it are continuously undergoing
proliferation, migration, and differentiation. At the same
time, the barrier retains the plasticity to rapidly respond to
changes in the luminal environment, such as the passage of
food or the presence of pathogens. The epithelium is ex-
posed to a myriad of endogenous and exogenous stimuli,
many of which have the capacity to alter one or several
aspects of barrier function. In the following sections we
discuss the role that bile acids play in this vital aspect of
epithelial function.
1. Cell death and survival
Epithelial cells, particularly those of the intestinal tract, are
being constantly renewed. This regeneration process re-
quires programmed elimination of damaged cells, usually
via the apoptotic cell death pathway, balanced with a con-
stant source of newly dividing cells. This finely-tuned bal-
ance between epithelial regeneration and death can become
disturbed in various pathophysiological conditions, leading
either to loss of barrier and transport function on the one
hand, or to the development of cancer on the other. The
roles of bile acids in regulating cell death and survival have
been widely investigated in different epithelial cell types
along the gastrointestinal tract, including those from the
small and large intestine, the liver and biliary tree, and the
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pancreas. While there is still much to learn, it is clear that
the response of epithelial cells from different tissues and
organs depends both on the bile acids to which they are
exposed and on the complement of receptors and signaling
pathways expressed.
Several studies have shown that DCA, a major secondary
bile acid, induces epithelial proliferation at concentra-
tions that would be expected to occur under normal con-
ditions in the colonic lumen. The molecular pathways
involved are complex and in various systems have been
shown to involve recruitment of the EGFr, with conse-
quent activation of extracellular signal-regulated kinase
(ERK). ERK then induces the upregulation of cyclooxy-
genase-2 and the basolateral release of prostaglandins,
which stimulate mitogenesis (66, 297). Proliferative ac-
tions of bile acids have also been shown to be mediated
by PKC (410), which can also be activated downstream
of the EGFr or through bile acid-induced membrane per-
turbations (5). Indeed, ligand-dependent transactivation
of the EGFr appears to be a common pathway underlying
proliferative actions of bile acids throughout the intestine
(26, 317, 380). Furthermore, such mitogenic actions of
bile acids appear to be antagonized by an FXR-mediated
pathway which inhibits EGFr-dependent signaling and
cell proliferation (105, 357). Studies from mammary ep-
ithelial cells indicate that FXR activation may also inhibit
EGFr-dependent signaling by downregulating expression
of other members of the ErbB receptor family with which
it heterodimerizes (135). Interestingly, GR and VDR ac-
tivation have also both been shown to be coupled to
inhibition of EGFr signaling and expression, suggesting
that bile acids may also have the capacity to influence
growth factor-dependent signaling through these path-
ways (290, 382).
While bile acids clearly have important roles in controlling
the rate at which cells proliferate, they are also equally
important in determining how long cells survive through
their actions in modulating apoptotic pathways. Apoptosis
is a highly regulated process of programmed cell death,
necessary for normal homeostasis of epithelial cells along
the crypt-villus axis (148). The complex molecular mecha-
nisms underlying apoptosis have been extensively reviewed
elsewhere, and only a brief overview is provided here (33,
61, 114). Apoptosis typically occurs in response to cellular
stresses, including a range of intracellular and extracellular
stimuli, such as inflammatory mediators, pathogens, reac-
tive oxygen species (ROS), and endoplasmic reticulum (ER)
stress, to name but a few, and can be divided into two
interrelated pathways, extrinsic and intrinsic. The intrinsic
pathway, as the name suggests, arises from intracellular
signals that ultimately lead to Bax-mediated increases in
mitochondrial membrane permeability (MMP) and release
of cytochrome c and other regulatory proteins, such as
XIAP and Smac/Diablo. Cytochrome c activates apoptotic
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FIGURE 5. Bile acids in regulation of colonic epithe-
lial Cl secretion. Under normal circumstances bile
acids (BA) are present in the colon at relatively low
concentrations where they inhibit Cl and fluid secre-
tion, thereby promoting normal colonic absorptive
function. This effect is mediated by farnesoid X recep-
tor (FXR)-induced downregulation of cystic fibrosis
transmembrane conductance regulator (CFTR) Cl
channel expression and Na-K-ATPase pump activ-
ity. Pathological conditions (depicted by red arrows)
that cause bile acid malabsorption in the ileum or
increased hepatic synthesis lead to increased delivery
of bile acids to the colon where they can act directly
on the epithelial cells to elevate levels of the prosecre-
tory second messengers, Ca2 and cAMP. In turn,
these second messengers rapidly stimulate the activ-
ity of the proteins that comprise the Cl secretory
pathway and the consequent fluid secretion into the
lumen causes diarrhea. Such fluid secretory re-
sponses to bile acids are amplified by recruitment of
the mucosal immune system and activation of enteric
nervous reflexes and are accompanied by concommi-
tant inhibition of fluid absorption (see text for details).
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protease activating factor (APAF1) which binds caspase 9,
leading to formation of the apoptosome, and subsequently
activation of caspases 3, 6, and 7, which function as execu-
tioners. In contrast, the extrinsic pathway is initiated by
extracellular signals, such as tumor necrosis factor-
(TNF-). These ligands activate the Death Receptors,
which are members of the TNF receptor family, including
TRAILR1, TNFR1, and FAS/CD95. Binding of TNF- to
TNFR1 leads to recruitment of TRADD (or FADD in the
case of FAS/CD95 activation) and procaspase 10, in turn
leading to activation of caspase 8, and subsequent acti-
vation of the executioner caspases. Importantly, the two
pathways do not function independently with the extrin-
sic pathway having the capacity to recruit the intrinsic
pathway through elevating levels of the cytosolic protein
BID. Ultimately, whether it is by the intrinsic or extrinsic
pathways, activation of caspases leads to cleavage of poly-
(ADP ribose) polymerase (PARP), disruption of the cellular
cytoskeleton and nuclear matrix proteins, DNA fragmenta-
tion, membrane blebbing, and finally disintegration of the
cell into apoptotic vesicles.
The effects of bile acids on pro- and anti-apoptotic path-
ways in epithelial cells are complex and appear to be highly
dependent on context. On the one hand, depending on the
particular cell type and levels of bile acids present, inhibi-
tion of apoptosis can occur, and this is thought to augment
proliferative responses to bile acids (292). Notably, activa-
tion of the bile acid receptors PXR, VDR, and TGR5 have
all been shown to prevent apoptosis in various epithelia
from the intestine and biliary tree (137, 258, 380, 524). In
contrast, activation of FXR has been reported to promote
apoptosis of transformed cells (308), thereby complement-
ing its antiproliferative and tumor suppressor activity de-
scribed above. Thus the relative expression and activation
of different bile acid nuclear receptors is likely to be an
important factor in determining epithelial cell fate.
Many studies have focused on investigating the effects of
bile acids in pathological conditions when epithelial cells of
intestine are exposed to abnormally high levels of bile acids
(150). Under these conditions, increased apoptotic cell
death is thought to contribute to associated losses of epithe-
lial barrier and transport function (33). There is a consid-
erable amount of evidence showing that there is a correla-
tion between increasing bile acid hydrophobicity and induc-
tion of apoptosis. Thus hydrophobic bile acids, such as
CDCA, DCA, and LCA, are generally thought be pro-apo-
ptotic, while the relatively hydrophilic bile acid UDCA is
anti-apoptotic (33, 433). The mechanisms involved in the
pro-apoptotic effects of hydrophobic bile acids in entero-
cytes appear to differ from those that occur in hepatocytes
during cholestasis. Whereas in the liver, both intrinsic and
extrinsic pathways are important, in the intestinal epithe-
lium bile acid-induced apoptosis appears to occurmainly by
the intrinsic pathway (33, 399, 477). Thus, in various in
vitro and in vivo models, apoptosis in response to hydro-
phobic bile acids has been shown to involve oxidative
stress-mediated activation of Bax, disruption of the MMP,
release of cytochrome c, apoptosome formation, and ulti-
mately the activation of executioner caspases 3, 6, and 7
(182, 477, 515). Interestingly, while it is clear that bile acids
can promote epithelial apoptosis when they are present at
high levels, prolonged exposure can lead to the develop-
ment of apoptosis resistance and promotion of proliferation
(110, 411). This may, at least in part, underlie the correla-
tions that have been reported between elevated levels of
luminal bile acids and increased probability of colon and
esophageal cancer (see sect. VI).
In summary, whether exposure of epithelial cells to bile
acids promotes their survival, proliferation, or death de-
pends on many interrelated factors but probably most im-
portantly the pattern of receptors that are expressed and the
concentrations/types of bile acid to which the cells are ex-
posed (FIGURE 6). This is not surprising given that epithelial
cells in different regions of the intestine encounter bile acids
under very different contexts. For example, we would ex-
pect that in cholangiocytes and gallbladder epithelium,
which are exposed to high monomeric concentrations of
conjugated bile acids (1–3 mM), responses would differ
from those of enterocytes lining the colonic lumen, where
bile acids are normally deconjugated and levels are rela-
tively low (500 M). Elucidating the complex mecha-
nisms involved in these processes is as important as it is
challenging.
2. Bile acids and tight junctions
As described above, the ability of neighboring epithelial
cells to form tight junctions (TJs) with one another is critical
to the formation and maintenance of the intestinal barrier.
TJs are highly regulated and dynamic structures which pro-
vide a “gatekeeper” function to control the movement of
nutrients, fluid, electrolytes, microbes, and their toxins
from the luminal contents into the mucosa. As such,
changes in levels of endogenous or exogenous factors that
regulate the expression and activity of TJ proteins can have
dramatic consequences for intestinal health and disease
pathogenesis. Several studies have demonstrated that TJ
function is regulated by luminal bile acids. For example,
incubation of cultured Caco-2 cell monolayers or human
colonic biopsies with dihydroxy bile acids reversibly de-
creases transepithelial resistance (TER) and induces phos-
phorylation and redistribution of the TJ junction protein
occludin (315, 375). The mechanisms underlying such ac-
tions have not been well-elucidated but appear to involve
recruitment of the EGFr and generation of ROS (19, 375).
Other studies in esophageal epithelial cells have demon-
strated that treatment with a combination of bile acids, in
the presence of acid, decreases TER by modulating the ex-
pression of claudins 1 and 4 (63).
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A role for bile acids in regulating TJ permeability is also
supported by in vivo studies in animal models. For example,
studies in mice fed a high-fat diet have shown that increases
in epithelial permeability and decreased expression of the
TJ proteins ZO-2 and JAM-A are associated with increased
colonic bile acids (316). Studies in mouse and rat bile duct
ligation models, where intestinal delivery of bile acids is
ablated, also reveal increased gut permeability and bacterial
translocation associated with decreased expression of oc-
cludin and claudin-2 (184, 470). Interestingly, FXR activa-
tion decreased the severity of intestinal inflammation in
these models, an effect that was associated with increased
expression of occludin and claudin-1, normalized permea-
bility, and reduced bacterial translocation. While it remains
to be determined if such actions are due to direct effects of
FXR activation on TJ protein expression, or if they are
indirect actions resulting from altered immune cell recruit-
ment to the mucosa, these studies suggest an important
protective role for FXR in preventing dysregulation of the
intestinal barrier (470). In addition to FXR, TGR5 has also
been identified as a regulator of TJ function, since TGR5/
mice display altered expression of TJ proteins, particularly
ZO-1 and occludin, have increased intestinal permeability
to macromolecules, and are more susceptible to the devel-
opment of experimental colitis compared with wild-type
controls (72).
3. Bile acids and the mucus layer
Epithelial cells of the intestine secrete a number of factors
that serve to enhance the physical barrier posed by the cells
themselves and their TJs. Perhapsmost important of these is
the mucus layer which overlies the epithelium and which
serves to maintain hydration of the mucosal surface, pre-
vent abrasion by digested food particles as they move
through the lumen, and protect against invasion by patho-
gens. Mucus is primarily produced by goblet cells along the
intestinal tract, but transporting enterocytes also have the
capacity to synthesize and secrete mucins. The organization
of the protective mucus layer is not constant along the in-
testinal tract, with the small intestine being covered by a
single nonattached layer and the stomach and colon having
two layers, a dense inner layer that is firmly attached to the
epithelium and a looser outer layer derived from proteolytic
cleavage of the inner layer (193, 352). The inner layer is
normally impenetrable to bacteria, while the outer layer
provides an environment in which commensal bacteria re-
side (192, 193). The primary component of mucus in the
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FIGURE 6. Bile acids in regulation of epithelial cell proliferation and death. Bile acids can induce epithelial
proliferation through recruitment of epidermal growth factor receptor (EGFr)-dependent signaling mechanisms
(blue arrows). Transactivation of the EGFr occurs through activation G protein-coupled receptors (GPCRs),
such as the muscarinic M3 receptor and TGR5. GPCR activation leads to EGFr activation through the release
of ligands, such as amphiregulin or transforming growth factor (TGF)-. Bile acid-induced membrane pertur-
bations can also lead to EGFr activation but in a ligand-independent fashion. Activation of EGFr leads to induction
of a pro-proliferative pathway, involving downstream activation of ERK mitogen-activated protein kinases
(MAPKs). EGFr activation also leads to stimulation of nuclear factor B (NFB) which prevents apoptosis,
thereby promoting cell survival and proliferation. Conversely, bile acids also have the capacity to stimulate
epithelial apoptosis (red arrows). This occurs, least partly, through bile acid-induced accumulation of reactive
oxygen species (ROS), leading to cellular cytotoxicity, loss of mitochondrial membrane potential (MMP), release
of cytochrome c, and consequent activation of the intrinsic apoptotic pathway. The balance between prolifer-
ation and apoptosis is closely regulated and is largely dependent on epithelial cell type and the concentration
and hydrophobicity of the bile acids present.
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stomach is MUC5AC and in the ileum and colon is MUC2,
both of which are secreted from goblet cells. However, en-
terocytes of the small intestine and colon also produce
transmembrane mucins, such as MUC3 and MUC7, that
not only contribute to the mucosal barrier but also have
important signaling roles in regulation of growth, differen-
tiation, and inflammation (352, 465). Mucins are highly
glycosylated with the attached sugar moieties acting as at-
tachment sites and providing nutrients for the resident mi-
crobiota (21).
Studies in rat and rabbit colon have demonstrated that
pathologically high (i.e., mM) concentrations of unconju-
gated bile acids, including DCA and CDCA, promote mu-
cus secretion, while their corresponding conjugated deriva-
tives are less effective (32, 53, 388). Such findings suggest
that mucus secretion, coordinated with fluid secretion, is
likely to be a protective mechanism that prevents epithelial
damage when concentrations of bile acids in the lumen are
abnormally high. Induction of mucus secretion by bile acids
has also been proposed to protect against bacterial infection
(452). Recent studies have also shown that the protective
effects of the taurine conjugate of UDCA (TUDCA) in ex-
perimental colitis in vivo are also associated with increased
colonic mucus secretion (245). Studies in cultured epithelial
cells from the stomach or colon also support a role for
unconjugated bile acids in promoting the secretion of
MUC2 (250), an effect that is mimicked by synthetic ago-
nists of FXR (506).
Interestingly, some studies have shown that relatively
low, physiologically occurring, concentrations of DCA
are sufficient to induce MUC2 expression in cultured
colonic epithelial cells (230, 426), while others showed
that chronic (i.e., 7 days) exposure to physiologically
relevant levels of DCA inhibited colonic epithelial mucus
production (414). Thus, while it seems likely that luminal
bile acids contribute to regulation of barrier function
through their effects on mucus secretion, there is still
much work to be done to understand the molecular
mechanisms involved and the physiological/pathophysi-
ological consequences of changes to the mucus layer in-
duced by different bile acids.
When considering how bile acids regulate mucus secretion,
one must also consider how they affect the production of
various epithelial-derived substances that serve to enhance
its barrier properties. For example, antimicrobial peptides
(AMPs) are secreted into the mucus layer where they act to
prevent bacterial penetration to the epithelium (16). Among
the AMPs expressed throughout the intestine are cathelici-
din and the defensins, of which there are several types
broadly divided into those secreted from ileal Paneth cells,
the -defensins, and those which are produced by entero-
cytes [i.e., the -defensins (HDs)] (493, 494). AMPs play
critical roles at the interface of microbial/epithelial commu-
nication in that they help to maintain sterility of the inner
mucus layer, and they contribute to determining the
makeup of the microbiome, regulate epithelial wound heal-
ing, and induce recruitment of immune cells to the mucosa.
Despite such a central role in mediating crosstalk between
the microbiota and the host, there is still little known of the
role that bile acids play in their regulation. However, that
such actions are likely to be important is evidenced by a
number of experimental studies in vitro and in vivo. For
example, in hepatic epithelial cells, CDCA, via FXR activa-
tion, promotes cathelicidin expression (83), while LCA, via
activation of the VDR, has been shown to induce expres-
sion of this AMP in cultured colonic epithelial cells (446). In
vivo studies using a mouse model of cirrhosis have shown
that FXR activation upregulates ileal -5-defensin in asso-
ciation with improved barrier function (457). Furthermore,
a direct association between bile acids, the microbiome, and
AMP production was demonstrated in recent studies by
Joyce et al. (199), where changes in expression of microbial
bile salt hydrolase, with concomitant increases in levels of
unconjugated bile acids, led to increased ileal expression of
the antibacterial protein RegIII. Our own studies of co-
lonic epithelial cells show that secondary bile acids differ-
entially regulate the expression of HDs in colonic epithe-
lial cells, with DCA promoting both HD1 and HD2 se-
cretion and UDCA having antisecretory effects (242).
However, much more work is needed to understand how
different microbial populations in the gut alter the intestinal
bile acid pool to regulate defensin secretion, and more im-
portantly, how these interactions impact on intestinal
health.
Another important protein secreted into the mucus layer by
the epithelium is secretory immunoglobulin A (sIgA). Syn-
thesized in Peyer’s patches, sIgA is transported across the
epithelium and secreted into the lumen, where it plays crit-
ical roles in promoting barrier function through blocking
bacterial penetration of the mucus, altering epithelial sig-
naling responses to commensal bacteria, and promoting the
activation of mucosal immune cells (276, 283). While the
microbiome is known to be an important regulator of epi-
thelial IgA secretion (155), whether bile acids also have
roles to play in this regard is an important area of research
that is yet to be addressed.
4. Bile acids and epithelial secretion of cytokines
If luminal pathogens evade the defense mechanisms
posed by the mucus layer, a second line of defense, the
innate immune response, is triggered in an attempt to
clear the invading species. Again, through the regulated
release of a range of mediators, chemokines, and cyto-
kines, the epithelium plays a key role in initiation of this
response. These messengers have diverse physiological
actions within the intestine and beyond, but essentially,
they serve to recruit, differentiate, and activate innate
immune cells to the mucosa. In turn, these cells engulf
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invading pathogens and release additional mediators that
promote inflammation, tissue remodeling, edema, and
recruitment of the acquired immune response. The pep-
tide, protein, lipid, and chemical mediators released by
the epithelium to control mucosal inflammation are vast
in number and have been extensively reviewed elsewhere
(186, 203, 359). However, particularly important are
thought to be cytokines, such as TNF-, interleukin
(IL)-8, and interferon (IFN)-, which contribute to the
recruitment and activation of immune cells, while anti-
inflammatory cytokines, such as IL-10, and other factors,
including resolvins and lipoxins, serve to dampen or
switch off the inflammatory response (116, 498).
There is little doubt that the release of cytokines and other
mediators from epithelial cells is key to regulating inflam-
matory responses that occur in various conditions associ-
ated with elevated levels of luminal bile acids (107, 204,
249, 434). Numerous studies on cells and tissues derived
from the liver, intestinal tract, and pancreas have also
shown that bile acids can act directly on epithelial cells to
modulate production of proinflammatory cytokines, such
as IL-8, IL-1, and IL-6 (18, 246, 314, 356, 437). Further-
more, how epithelial cells respond depends on the bile acid
in question. For example, DCA and its taurine conjugate,
TDCA, both stimulate NFB-dependent IL-8 release from
colonic epithelial cells, although considerably higher levels
of TDCA are required to induce a response (314), In con-
trast, UDCA and its conjugated derivative, TUDCA, have
been shown to inhibit cytokine release from cultured epi-
thelial cells in vitro and reduce mucosal accumulation of
TNF- and IL-1 in vivo (245, 280, 392). In addition to
cytokines, epithelial production of other inflammatory me-
diators, such as prostaglandins (36, 76, 439), leukotrienes
(103), nitric oxide (185), and ROS (19, 80), have also been
shown to be increased in response to bile acids in various
different models.
Finally, it should also be noted that in addition to regu-
lating mucosal immune cells indirectly through epithelial
cytokine release, bile acids can also exert direct actions
on the immune cells themselves. For example, dihydroxy
bile acids have shown to activate and degranulate mast
cells causing local histamine release (130, 373). In con-
trast, activation of FXR or TGR5 on innate immune cells,
such as macrophages, monocytes, and dendritic cells, ap-
pears to suppress expression of various pro-inflamma-
tory cytokines (128, 181, 364, 513). Bile acids also ap-
pear to suppress the proliferation of lamina propria lym-
phocytes (115). Thus how alterations in the levels of
luminal bile acids influence gut function, both under nor-
mal circumstances and under conditions of infection or
inflammation, ultimately depends on a complex interplay
of pro- and anti-inflammatory mediators released from
both epithelial and immune cells.
VI. PATHOLOGICAL EFFECTS OF BILE
ACIDS
From the preceding sections, it is clear that in addition to
their digestive functions, bile acids have crucial roles to play
in normal regulation of intestinal homeostasis. Alterations
in either the size or composition of the bile acid pool can
have a dramatic impact on intestinal function, and thus the
enterohepatic circulation is a tightly regulated process, un-
der the control of numerous intrinsic and extrinsic factors
(91, 167). Normally, most of the circulating bile acids (90–
95%) are reclaimed in the distal ileum and returned to the
liver, with only a small fraction entering into the colon (see
sect. I for details). However, if the EHC becomes dysregu-
lated, this can lead to significant alterations, not only in the
size and makeup of the bile acid pool, but also in the range
of tissues and organs exposed to thesemolecules (FIGURE 7).
For example, malabsorption in the ileum can lead to greatly
increased levels of bile acids entering the colon, impaired
FGF19 secretion can produce greater bile acid pool size
with greater loss into the colon, cholestasis can result in bile
acids entering the pancreas, whereas GERD can be accom-
panied by bile acids entering the esophagus, and from there
into airways. In each of these pathological scenarios, dys-
regulated epithelial cell function has been well-established
to be a central aspect of disease progression.
A. Bile Acids in Chronic Diarrhea and
Constipation
As discussed in earlier sections, increased delivery of bile
acids to the colon can occur either as a consequence of ileal
resection or dysfunction or because of defective FGF19 re-
lease from ileal enterocytes. In either case, increased levels
of deconjugated bile acids in the colon can have profound
actions on epithelial function, inhibiting Na absorption,
stimulating Cl secretion, and enhancing permeability. The
resulting accumulation of fluid in the colonic lumen leads to
the onset of what has become known as bile acid diarrhea
(BAD) (218, 312, 334)]. In addition, elevated levels of lu-
minal bile acids are also well-established to promote intes-
tinal motility through neuronally mediated pathways (123,
355, 422), effects that are now known to be mediated by
neuronal TGR5 (8, 216, 369). Thus, in conditions of BAD,
intestinal transit is also accelerated, thereby contributing to
the onset of diarrhea in these patients. Indeed, a recent
study of irritable bowel syndrome with diarrhea (IBS-D)
patients shows that even in the absence of overt bile acid
malabsorption, by virtue of their prokinetic effects, modest
increases in stool bile acids can be an underlying factor in
the onset of diarrhea (353).
When BAD is due to malabsorption of bile acids in the
ileum, whether this is due to congenital absence of bile acid
transporters, ileal inflammation, or surgical resection, it is
classified as being type I (or secondary) BAD. On the other
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hand, BAD in the absence of ileal pathology is classified as
being type II (or primary) disease. Although primary BAD
(pBAD) has long been considered an idiopathic disease,
recent years have seen great advances in our understanding
of its prevalence and pathogenesis. Recognition of its high
prevalence has been obtained by SeHCAT testing, a diag-
nostic tool which uses a 75Se-tagged radionuclide bile acid
homologue to monitor turnover of the bile acid pool. Stud-
ies with this test have shown that at least 30% of patients,
who would normally be diagnosed as having IBS-D, actu-
ally suffer from pBAD (239, 421, 492). The condition is
highly prevalent, affecting at least 1% of the population of
Western societies.
It is now known that pBAD occurs due to a defect in FXR/
FGF19/FGFR4 axis in regulation of the EHC. Under nor-
mal circumstances, bile acid uptake at the apical surface of
ileal enterocytes via ASBT activates intracellular FXR and
induces transcription of FGF19. FGF19 is then secreted via
the basolateral membrane of the enterocyte into the EHC
and travels to the liver where it downregulates bile acid
biosynthesis by inhibiting CYP7A1 expression (cf. FIGURE
1) (424, 482). In pBAD, FXR induction of FGF19 expres-
sion is impaired, resulting in an increase in bile acid biosyn-
thesis, increased colonic delivery, and consequently the on-
set of diarrhea. Studies have shown that, in patients with
pBAD, ileal bile acid uptake is unaltered and there is a larger
bile acid pool. This contrasts with an expected reduction if
ileal malabsorption rather than increased hepatic synthesis
was the predominant pathology. Current research in this
area is focused on the identification of biomarkers for
pBAD and in determining the causative factors leading to
reduced FGF19, which are likely to be multiple (185, 479).
Some patients have hypertriglyceridemia, and patterns of
impaired/meal-stimulated FGF19 responses can be found.
While no clear causative genetic variants of FXR, FGF19,
or the bile acid transporters are apparent, allelic variants of
the FGF19 receptor FGFR4 or the co-receptor Klotho-beta
may be present in a subset of pBAD patients, resulting in
hyporesponsiveness to the hormone in the liver (194).
As noted previously, the diarrhea associated with increased
colonic bile acids may represent an innate protective mech-
anism, whereby luminal fluid accumulation dilutes poten-
tially cytotoxic bile acids, such as DCA and LCA, before
they can achieve levels that cause epithelial damage and loss
of function. This idea is supported by observations that,
despite elevated levels of colonic bile acids, BAD is not
associated with significant changes in mucosal histology
(403). However, BAD is a chronic disease, and the quality
of life for patients suffering with the condition is severely
impacted due to fecal incontinence, urgency, abdominal
pain, and often anxiety and depression (31). Despite its
prevalence, BAD remains underdiagnosed and treatment
options are limited. Bile acid binding resins, such as
cholestyramine, can be of benefit, but their use is limited by
poor patient tolerance, bloating, mucoadherence, and drug-
drug interactions (52, 481). A new bile acid sequestrant that
binds bile acids more efficiently, colesevelam, is available in
tablet form and appears to have less adverse effects. A
proof-of-concept study suggests that FXR agonists, by stim-
ulating FGF19 production, could also have a future role in
the therapy of this disorder (see below) (455).
Just as the delivery of abnormally high levels of bile acids to
the colon is an underlying cause of diarrhea, so too can
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FIGURE 7. Pathological consequences of enterohe-
patic circulation (EHC) dysregulation. Blue solid lines de-
pict the normal EHC, where bile acids are released from
the liver into the small intestine to facilitate lipid digestion
and absorption. Approximately 95% of released bile ac-
ids are reabsorbed from the small intestine and are
recycled to the liver through the EHC. A small proportion
(~5%) normally enters the colon where bacterial metab-
olism, followed by either passive reabsorption or excre-
tion in the feces, occurs. Red dashed lines depict condi-
tions associated with dysregulation of the EHC. Malab-
soprtion or increased biosynthesis of bile acids results in
their increased delivery to the colon, causing bile acid
diarrhea or contributing to the pathogenesis of inflamma-
tory bowel disease (IBD), irritable bowel syndrome (IBS),
and colorectal cancer (CRC). Blockage of bile flow to the
small intestine can result in reflux into the pancreas, con-
tributing to the onset of pancreatitis. In gastroesophageal
reflux disease (GERD), bile refluxes into the esophagus,
causing esophagitis and progressing to Barrett’s esopha-
gus and cancer. From the esophagus, aspiration of bile
acids into the airways can lead to the development of fibro-
sis, pneumonia, and respiratory distress syndrome.
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abnormally low levels be involved in the pathogenesis of
chronic constipation. A recent retrospective study by Ca-
milleri and co-workers has shown that ~15% of patients
with irritable bowel syndrome with constipation (IBS-C)
have decreased levels of bile acids in their feces and that this
correlated with increased colonic transit time (471). De-
creased biosynthesis in the liver, as indicated by elevated
FGF19 and reduced C4 in the serum, appears to be a factor
underlying reduced fecal bile acids in these patients. Indeed,
simply restoring levels of luminal bile acids by oral admin-
istration of CDCA appears to be an effective treatment for
patients diagnosed with either IBS-C or chronic constipa-
tion (37, 377). An alternative approach currently under
investigation for increasing colonic bile acids in treatment
of constipation is the use of ASBT inhibitors, such as elo-
bixibat, that prevent bile acid absorption in the terminal
ileum (2) (see sect. VI). In addition to their reduced colonic
delivery, altered bile acid metabolism may also contribute
to constipation in some patients. For example, patients with
IBS-C have been shown to have reduced amounts of prose-
cretory bile acids, such as DCA and CDCA, in their feces
(416), while in a subset of pediatric patients with chronic
constipation the predominant fecal bile acid is 3-sulfo-
CDCA, which unlike CDCA does not stimulate intestinal
fluid secretion (169).
B. Bile Acids and IBD
Inflammatory bowel diseases are a group of conditions as-
sociated with chronic recurring inflammation of the intes-
tinal mucosa. The most common of these conditions are
ulcerative colitis (UC) and Crohn’s disease (CD), which are
estimated to affect 0.5–1% of the population of Western
societies and which are associated with symptoms of ab-
dominal pain, diarrhea, fatigue, rectal bleeding, and weight
loss (1, 207). Patients suffering from IBD also experience
psychological comorbidities due to increased prevalence of
anxiety and depression (300, 321) and have an increased
risk for the development of colorectal cancers (126, 386).
There is currently no cure for IBD, and treatment aims
primarily to induce, and then maintain, remission through
the use of anti-inflammatory drugs, such as 5-aminosalicy-
lates, steroids, immunosuppressants, and biologics target-
ing TNF- (323, 367). However, since such drugs can be
expensive, may have severe side effects, and are often inef-
fective, new treatment options are urgently required.
While the triggers for IBD are still not fully understood,
both genetic and environmental factors appear to be impor-
tant in leading to dysregulated mucosal immune responses
(96, 486). Hallmark features of the disease also include
enhanced epithelial permeability and alterations to the res-
ident microbiota (15, 298, 374), althoughwhether these are
a cause or consequence of the disease is still not certain.
Studies showing that asymptomatic relatives of IBD pa-
tients also have enhanced epithelial permeability and dis-
tinct microbial fingerprints suggest that such alterations
may be necessary, but not sufficient, for disease progression
(136, 142, 156, 225). Furthermore, changes in the profile of
luminal bile acids have also been closely associated with
IBD progression. Such changes can occur as a consequence
of a dysregulated enterohepatic circulation, leading to in-
creased delivery of bile acids to the colon (188, 327, 378,
473). Changes in the luminal bile acid profile in IBD have
also been closely linked to changes in the microbiota (107,
327, 473). For example, recent studies by Duboc et al. (107)
have demonstrated that altered enzymatic activity within
the microbiota of IBD patients alters the colonic bile acid
profile towards increased levels of conjugated and sulfated
bile acids. Other studies in mouse models indicate that con-
sumption of a high-fat diet shifts hepatic conjugation of bile
acids from glycine to taurine, resulting in enhanced gener-
ation of sulfur in the colonic lumen. In turn, this promotes
growth of bile-tolerant bacteria, most notably Bilophila
Wadsworthia, which promote Th-1-mediated mucosal im-
mune responses (100). Still further studies suggest that dys-
regulated signaling via bile acid receptors may also have a
role to play in disease progression, given that SNPs in FXR
and altered receptor expression and activity have been
shown to be associated with CD and UC (25, 325). Given
their crucial roles in regulating intestinal epithelial apopto-
sis and proliferation, TJ permeability, and water, cytokine,
and mucus secretion (cf. sect. IV), it is perhaps not surpris-
ing that alterations in luminal bile acids contribute to
pathogenesis of intestinal inflammation. Indeed, studies
have demonstrated that bile acids may underlie the en-
hanced epithelial permeability associated with disease pro-
gression (434). However, the precise roles that bile acids
play in IBD pathogenesis is still uncertain and whether they
act as promoters or inhibitors of inflammation likely de-
pends on several factors, including their concentration,
physicochemical properties, and the resident microbiota
(350). For example, DCA, when present at abnormally high
levels, has been shown to enhance inflammation in an ani-
mal model of colitis through NLRP3 inflammasome activa-
tion (523). In contrast, feeding with CDCA has been shown
to prevent inflammation in the DNBSmodel of colitis (143),
an effect which may be due to colonic generation of the
CDCA metabolite UDCA, which has well-established anti-
inflammatory and cytoprotective actions. Despite our still
limited understanding of complex roles that bile acids play
in regulating intestinal inflammation, studies in animal
models which demonstrate protective actions of synthetic
FXR and TGR5 agonists provide great promise for the de-
velopment of new bile acid-based therapeutics for IBD in
the future (28) (cf. sect. VI below).
C. Bile Acids and Cancer
Colorectal cancer (CRC) is the third most common form of
cancer inWestern countries and is responsible for ~700,000
deaths worldwide each year (22). While there are undoubt-
REGULATION OF INTESTINAL EPITHELIA BY BILE ACIDS
2001Physiol Rev • VOL 98 • OCTOBER 2018 • www.prv.org
Downloaded from www.physiology.org/journal/physrev at Univ of Szeged (160.114.106.153) on January 29, 2019.
edly genetic and environmental components to disease de-
velopment, relationships between diet, the resident micro-
biota, and bile acids have also long been suspected as im-
portant contributing factors (20, 163, 368, 379). Early
epidemiological studies showed strong correlations be-
tween CRC occurrence and levels of fecal bile acids, while
studies in animal models demonstrated that increased levels
of bile acids, whether they are due to ileal bypass surgery or
direct colonic instillation, promote tumor formation (164,
231, 404, 500). In contrast, a long-term study of human
patients with ileal bypass reported no overall increase in
cancer deaths over a 25-yr followup period (48). It should
be noted however that the latter study did not specifically
report on the incidence of CRC in these patients. Neverthe-
less, evidence has continued to accumulate to support the
hypothesis that interactions between diet, the microbiota,
and bile acids are key contributors to CRC development
(331), while our understanding of the molecular pathways
by which bile acids regulate epithelial cell death and sur-
vival in the colon has grown steadily (cf. sect. IV).
Factors that increase delivery and that shift the colonic pool
of bile acids towards a more hydrophobic profile (i.e., de-
conjugated and dehydroxylated) are associated with in-
creased risk of CRC development. Thus the Western diet,
which is rich in fat and low in fiber, leads to alterations in
the enterohepatic circulation leading to increased synthesis
and colonic delivery of bile acids (263, 316). At the same
time, alterations to the colonic microbiota, or dysbiosis,
cause a shift towards increased dehydroxylation and decon-
jugation, leading to the generation of secondary bile acids,
such as DCA and LCA (4, 161, 198, 338, 454). Elevations
in the levels of secondary bile acids in this way are believed
to increase epithelial permeability (316, 434), leading to
enhanced bacterial translocation and prolonged low-grade
mucosal inflammation, ultimately contributing to cancer
development. As discussed above, such increases in epithe-
lial permeability brought about by secondary bile acids
likely involve epithelial apoptosis, with cytotoxicity being
directly proportional to the lipophilicity of the luminal bile
acid pool (372). Interestingly, while increased apoptosis
might contribute to disruptions in epithelial barrier func-
tion, such actions would also be expected to prevent tumor
growth. However, it is thought that prolonged exposure of
the colonic epithelium to pathophysiological levels of lipo-
philic bile acids ultimately leads to overactivation of NFB
and development of apoptosis resistance, thereby promot-
ing tumor development (81, 411).
Another important way in which bile acid signaling appears
to be involved in the development of intestinal cancer is
through the nuclear receptor FXR, which has been shown
to be downregulated in tissues from patients with the dis-
ease (93, 247, 448) (FIGURE 8). The role of FXR has been
mostly studied in CRC, where in mouse models loss of FXR
expression is associated with increased size and number of
adenocarcinomas. Such effects appear to be multifactorial
and are related to enhanced Wnt signaling, expression of
cell cycle proteins, increased proliferation, and downregu-
lated apoptosis (277, 308). Given the importance of NFB
in development of apoptosis resistance to bile acids, recent
findings that FXR andNFB are reciprocally regulated may
provide an important insight into disease pathogenesis
(127, 467). While upregulation of NFB activity appears to
dampen FXR expression in cancer, other mechanisms are
also likely to be involved, including enhanced expression of
FXR-modulating miRNAs (235, 520). Acquired mutations
in the tumor suppression gene adenomatous polyposis coli
are also an important factor, leading to enhanced methyl-
ation of the FXR promoter and downregulation of CDX2,
a transcriptional regulator of FXR (30, 307, 406).
Interestingly, while FXR appears to play a protective role
against the development of CRC and gastric cancer (106),
the same is not true for all gastrointestinal cancers. For
example, in the esophagus, expression of FXR is poorly
correlatedwith disease outcome, and in direct contrast to its
actions in the colon, it prevents apoptosis in these tissues
(92, 147). Similarly, overexpression of FXR in other or-
gans, such as the pancreas or gallbladder, is a poor prog-
nostic factor where it appears to promote tumor growth
and metastatic potential (174, 251). Thus, while FXR is
now emerging as an important factor in the development of
cancer throughout the intestinal tract, its roles appear to be
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FIGURE 8. Farnesoid X receptor (FXR) downregulation in the
pathogenesis of colorectal cancer. The expression of FXR decreases
in colorectal cancers, an effect that has been proposed to be linked
to multiple factors, including the acquisition of mutations in the
tumor promoter, adenomatous polyposis coli (APC), expression of
miRs, and the consumption of a high-fat western diet. Downregula-
tion of FXR expression is thought to contribute to the pathogenesis
of colorectal cancers by multiple mechanisms, including alterations
in cell cycle proteins, activation of EGFr-dependent signaling, de-
creased apoptosis, and increased levels colonic bile acids. Reacti-
vation of FXR in colon cancers has been shown to prevent the growth
and development of tumors.
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tissue specific, and there is still much work to be done in its
development as a new target for chemotherapeutic inter-
ventions.
D. Bile Acids and Pancreatitis
Acute pancreatitis is the most common cause for hospital-
ization among nonmalignant gastrointestinal disorders
(244, 254, 271). In severe cases, the mortality of the disease
can reach 20–30% (346). Gallstones are the most common
etiological factors in acute pancreatitis in the Western
world. Small gallstones entering the common bile duct and
settling at the papilla of Vater can simultaneously block the
outflow of bile and pancreatic juice (158). The exact patho-
genesis of acute biliary pancreatitis is still a matter of de-
bate, with two theories predominating (253). According to
the common channel theory, bile acids reflux into the pan-
creatic ductal tree, whereas the duct obstruction theory em-
phasizes the role of increased pressure and outflow block-
age. Whatever the cause, studies from in vivo models sug-
gest that bile acids are likely to play a pivotal role, since
pancreatic duct ligation evokes only mild pancreatitis
(309), whereas simultaneous ligation of the bile duct signif-
icantly increases disease severity (407). Furthermore, infu-
sion of the bile acid taurolithocholic acid 3-sulfate (TLC-S)
into the pancreatic ducts of anesthetized mice has been
shown to induce acute necrotising pancreatitis, which is
likely in part due to increased NFATc3 activity, an enzyme
responsible for trypsinogen activation, inflammation, and
pancreatic tissue damage (27, 362). Interestingly, TGR5
knockout mice are protected against the onset of pancreati-
tis in this model, suggesting an important role for the recep-
tor in disease pathogenesis (361). Such protective effects are
associated with an attenuation of bile acid-induced Ca2
signals, intracellular activation of digestive zymogen gran-
ules, and cell injury as demonstrated in vitro on isolated
TGR5 knockout pancreatic acinar cells.
Key to mediating the toxic effects of bile acids on acinar
cells are changes in intracellular Ca2 levels (FIGURE 9).
TLC-S induces sustained elevations in cytosolic Ca2 due to
stimulation of Ca2 release from the ER and acidic Ca2
stores (131, 474), along with simultaneous inhibition of its
reuptake into the ER via SERCA pumps (227). Depletion of
Ca2 stores subsequently induces Ca2 influx from the ex-
tracellular space via store-operated Ca2 entry channels
(268), thereby maintaining cytosolic intracellular Ca2
concentration at high levels. In turn, such sustained in-
creases in intracellular Ca2 trigger damage to the mito-
chondrial membrane, intra-acinar trypsinogen activation,
and aberrant enzyme secretion, leading to acinar cell dam-
age and, ultimately, pancreatitis (104, 236, 415). Ca2-
independent mechanisms may also be involved in mito-
chondrial toxicity when higher (100 M) concentrations of
bile acids are present (475, 476). Schulz et al. (402) demon-
strated that, at such concentrations, bile acids can damage
the mitochondrial membrane, leading to decreased mito-
chondrial membrane potentials and cellular damage.
Bile acid actions on cells other than acinar cells are also
important in development of pancreatitis. For example,
pancreatic stellate cells (PSCs) are found in close apposition
to acinar cells and normally function in the maintenance of
the ECM through a balanced production and degradation
of ECM proteins (157). During tissue injury, excessive ac-
tivation of stellate cells induces increased production of
ECM proteins, leading to tissue fibrosis (149). Recent stud-
ies of mouse and human PSCs demonstrate that treatment
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FIGURE 9. Role of bile acids in pathogenesis of acute
pancreatitis. Although the pathogenesis of acute biliary
pancreatitis is still elusive, bile acids have been shown to
induce significant damage in the exocrine pancreas. In both
pancreatic acinar and ductal cells, bile acids induce Ca2
release from the endoplasmic reticulum (ER), leading to
sustained intracellular Ca2 overload. Elevated intracellular
Ca2 can, in turn, induce mitochondrial damage, thereby
decreasing intracellular ATP levels. In pancreatic acinar cells,
elevated Ca2 can promote auto-activation of trypsinogen to
trypsin, whereas in ductal cells, sustained intracellular Ca2
overload inhibits ion and fluid secretion. Ultimately, these ac-
tions result in autodigestion of the tissue and necrosis, which
are hallmarks of pancreatitis.
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with cholate or taurocholate induces large, sustained, in-
creases in intracellular Ca2 leading to necrosis (119). In-
terestingly, TLC-S had only a minor effect on Ca2 signal-
ing in PSCs, indicating a distinct responsiveness to bile acids
compared with their neighboring acinar cells.
Studies from the Hegyi group indicate that bile acids also
act on the epithelial cells of the ducts during pancreatitis. At
relatively low concentrations, the nonconjugated bile acid
CDCA stimulates pancreatic ductal HCO3
 secretion via
inositol trisphosphate-mediated Ca2 release and induction
of Cl/HCO3
 exchange activity, a response that may serve
as a protective mechanism against the presence of toxic bile
acids (183, 469). In contrast, when present at high concen-
trations, ductal CDCA causes mitochondrial damage and a
Ca2-independent inhibition of bicarbonate secretion (274,
469). In turn, this leads to intraluminal acidification, in-
creased autoactivation of trypsinogen, and generation of
trypsin, which then acts at PAR-2 receptors to downregu-
late HCO3
 exchange and CFTR (340, 341, 440). Recent
clinical studies, showing that intraluminal pH is signifi-
cantly lower in patients with acute biliary pancreatitis than
in controls, further support these observations.
E. Bile Acids and GERD
GERD is a highly common chronic condition associated
with esophageal mucosal inflammation, which can progress
to ulceration and metaplasia of the epithelium and increase
the likelihood of developing esophageal adenocarcinoma
(EA) (428, 487). First described in the 1800s, esophagitis
was even then assumed to be a condition caused by reflux of
stomach acid into the lower esophagus, causing intense
pain, the appearance of gastric-like ulcers, and ultimately
leading to esophageal perforation and death [reviewed in
Barrett, 1950 (35)]. Bile acids became appreciated for their
role in disease development in the early 1970s, with subse-
quent decades seeing much progress in understanding the
cellular and molecular mechanisms involved (159). Similar
to their actions in the lower intestine, the presence of bile
acids in the esophageal lumen induces alterations in the
expression of TJ proteins, such as claudin-1 and claudin-4
and induction of apoptosis, thereby contributing to the en-
hanced permeability and loss of barrier function associated
with GERD (42, 63, 132, 343). However, in addition to
dysregulated EEC barrier function, other studies suggest
that immune-mediated mechanisms are also likely to be
important and may even precede loss of epithelial barrier
function (429). Furthermore, several studies suggest that
bile acids are likely to contribute to this immune-driven
response, since exposure of esophageal squamous epithelial
cell lines and ex vivo mucosal tissues to bile acids signifi-
cantly increases expression of cyclooxygenase-2 and induc-
ible nitric oxide synthase, and secretion of the proinflam-
matory cytokines IL-8 and IL-1, leading to enhanced mi-
gration of T cells and neutrophils into the mucosa (191,
293, 417, 429). Increased expression of FXR in the epithe-
lium appears to be involved in mediating such responses
(54, 92, 460), and a combination of acidic media with bile
acids seems to be important. Interestingly, cytokine release
from human esophageal epithelial cells can be prevented by
the proton pump inhibitor omeprazole, an effect whichmay
contribute to the therapeutic actions of the drug in patients
with GERD (180).
A significant risk associated with GERD is development of
Barrett’s esophagus (BE), a condition estimated to affect
~6% of adults in the United States, in which the normal
stratified squamous epithelium differentiates into an intes-
tinal-type columnar epithelium (336, 430). BE is more com-
mon in Caucasians than other ethnic groups, and it has been
proposed the condition occurs when both genetic and envi-
ronmental factors combine to cause abnormal defensive
responses to esophageal refluxate (376, 381). Althoughmo-
lecular events underlying the pathogenesis of Barrett’s
metaplasia are not yet fully understood, it is clear that they
are multifactorial involving complex interactions among
developmental signaling pathways, morphogenetic factors,
and caudal homeobox (CDX) genes (134). CDX genes are
normally expressed in epithelial cells of the lower intestine
but not in the esophagus. However, in patients with esoph-
agitis, CDX1 expression increases, subsequently leading to
expression of CDX2, a transcription factor known to be a
critical regulator of epithelial differentiation (77, 113, 178,
214). Conditional deletion of CDX2 in the intestine of mice
leads to the formation of a squamous epithelium (129),
whereas ectopic expression of the protein in the esophagus
leads to the formation of a transitional epithelium, interme-
diate of squamous and columnar epithelia, with reduced
proliferation and compromised barrier function (232). Fur-
thermore, studies have shown that exposure to bile acids
can promote such “transcommitment” of normal esopha-
geal epithelial cells through repression of transcription fac-
tors, such as SOX2, that establish their normal squamous
phenotype and enhancing expression of those, such as
CDX2, that drive an intestinal columnar phenotype (62, 98,
179, 302, 442). Multiple upstream signaling mechanisms
appear to be involved in mediating bile acid-induced effects
on CDX2 expression, including ROS production via acti-
vation of NADPH oxidase NOX5-S, EGFr activation, acti-
vation of NFB, induction of cytokine secretion, and up-
regulation of trefoil factors (23, 178, 240, 423). The devel-
opment of BE is also associated with altered epithelial
transport function leading to a dysregulated acid/base bal-
ance and intracellular acidification (138).
BE is the main predisposing factor for the development of
EA, a condition with very low 5-yr survival rates and a
rapidly increasing worldwide incidence (12). Development
of EA from BE occurs progressively from low-grade dyspla-
sia to high-grade dysplasia and ultimately to invasive EA.
However, the incidence of BE progression to EA is very low,
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occurring in only ~0.5% of patients, and although the fac-
tors involved in driving this transition are still not well-
defined, they are multifactorial (74). Bile acids appear to
play an important role through induction of ROS produc-
tion, DNAdamage, and persistent NFB activation, leading
to apoptosis resistance (177). Although FXR expression
decreases during the transition fromBE to EA, levels remain
elevated with respect to normal esophageal epithelial cells,
with expression of the receptor being reported as a poor
prognostic factor. Interestingly, in contrast to its pro-apo-
ptotic actions in CRC (cf. sect. IV), FXR appears to prevent
apoptosis of EA cells, thereby promoting tumor growth,
while at the same time it downregulates expression of
CDX2, contributing to tissue dedifferentiation (92, 147,
285). Expression of TGR5 also increases as BE cells become
increasingly dysplastic and may contribute to cancer devel-
opment through induction of NOX-5S expression and gen-
eration of ROS (255, 279, 342).
F. Bile Acids and the Airways
Another important consequence of GERD is that refluxate
in the esophagus can enter the airways by aspiration, result-
ing in bile acids, acid, and digestive enzymes coming into
contact with the respiratory epithelia. One particular con-
dition of which this is a feature is cystic fibrosis where up to
60% of patients have been shown to have bile acids present
in their airways, with their presence being directly corre-
lated with inflammatory indexes and decreased lung func-
tion (43, 349). Patients that have undergone lung transplan-
tation are also at increased risk for bile acids entering the
airways where they may contribute to the development of
bronchiolitis obliterans syndrome (BOS), a common cause
of organ rejection (43, 84, 85). Bile acids have been also
associated with a poor prognosis in other conditions, such
as ventilator-associated pneumonia (505), idiopathic pul-
monary fibrosis (396), and respiratory distress syndrome
(516). The latter can be particularly important in the setting
of intrahepatic cholestasis of pregnancy (ICP), a condition
which typically occurs in the third trimester of up to 1% of
pregnancies inWestern countries (347). Several factors con-
tribute to the onset of ICP, including genetic, environmen-
tal, and hormonal influences, leading to dysregulation of
the enterohepatic circulation with a marked increase in lev-
els of maternal serum bile acids. As a consequence, bile
acids accumulate in the amniotic fluid and can contribute to
the onset of premature labor, infant respiratory distress,
and stillbirth. Several studies have demonstrated increased
levels of bile acids in the serum and bronchoalveolar lavage
fluid (BALF) of neonates with ICP-associated respiratory
distress (160, 514, 517, 518), while bile acids have also
been shown to be elevated in BALF of infants after sudden
infant death syndrome (165).
Despite these important clinical observations, until recently
bile acids have been mostly considered only as biomarkers
for aspiration of GERD, and their possible roles in modu-
lation of airway physiology has been largely neglected.
However, recent studies have begun to give significant in-
sights into the detrimental actions of BAs in the airways,
where they are proposed to promote damage through in-
duction of cytokine release (7, 365), increased alveolar per-
meability (438), fibrosis (60), degradation of surfactant
(95), and apoptosis (522). Furthermore, the presence of bile
in the airways can lead to biofilm formation by cystic fibro-
sis-associated respiratory pathogens, which may be an im-
portant factor contributing to airway colonization by op-
portunistic microorganisms (458). Themolecular pathways
by which bile acids exert their actions in the airways are still
poorly defined, although recent studies have implicated
FXR in mediating their effects on airway epithelial survival,
epithelial-mesenchymal transition, and activation of fibro-
blasts (59, 485). However, other studies demonstrating
protective actions of FXR against airway inflammation and
fibrosis suggest that there is still much to be learned of how
this, and indeed other bile acid receptors, contribute to
airway health and disease (78).
VII. THERAPEUTIC TARGETING OF BILE
ACIDS IN INTESTINAL DISEASE
Given that bile acids perform so many critical roles in reg-
ulating intestinal physiology and pathophysiology, they
provide excellent targets for development of new therapeu-
tic interventions. Exploitation of bile acid-dependent regu-
latory mechanisms can be achieved either by the use of
pharmaceuticals that target bile acid receptors and trans-
porters, or alternatively, by indirect approaches that alter
the luminal bile acid signature. In this final section, we
briefly review the state of the art with respect to therapeutic
targeting of bile acids which, at least at the time of writing,
provides an index of how bile-acid-directed therapeutics
may look in the future.
A. Bile Acid Receptor Modulators
The discovery of the FXR and TGR5 as nuclear and cell
surface receptors for bile acids at the turn of the millennium
represented a huge step forward in our ability to therapeu-
tically manipulate bile acid-dependent regulatory mecha-
nisms. Since its discovery, the crystal structure of FXR has
been resolved, giving medicinal chemists the opportunity to
apply rational drug design approaches in development of
new receptor ligands (299, 413). A number of specific ago-
nists have so far been developed, such as GW4064, PX-102,
LJN452, and Ec001, but with only one to date having made
its way into clinical use. In 2016, obeticholic acid (OCA),
the 6-ethyl derivative of CDCA, became the first synthetic
bile acid to be approved by the FDA for use in patients.
Marketed as Ocaliva, OCA is currently used in combina-
tion with UDCA for treatment of primary biliary cholangi-
REGULATION OF INTESTINAL EPITHELIA BY BILE ACIDS
2005Physiol Rev • VOL 98 • OCTOBER 2018 • www.prv.org
Downloaded from www.physiology.org/journal/physrev at Univ of Szeged (160.114.106.153) on January 29, 2019.
tis (10) and is also in clinical trials for other liver diseases,
including NASH and primary sclerosing cholangitis (9,
248, 499). However, given the central role that FXR plays
in regulation of many extrahepatic aspects of human phys-
iology, it is likely that agonists of the receptor will find
additional therapeutic uses in the future. Based on its im-
portant roles in cholesterol, lipid, and carbohydrate metab-
olism, FXR agonists are also currently under investigation
for metabolic disorders, such as obesity, diabetes, and car-
diovascular disease (24, 257, 310, 408). With respect to
intestinal diseases, preclinical studies in the DSS model of
intestinal inflammation in mice suggest that FXR agonists
might also be of use in treatment of IBD (128, 435). Based
on our own studies demonstrating that FXR agonists in-
hibit fluid secretion into the gut (313), it is possible that
such drugs may also have a future role in the treatment of
diarrheal diseases. Patients with BAD could be expected to
particularly benefit from the use of FXR agonists, since such
drugs would be expected not only to inhibit colonic fluid
secretion but also to reduce bile acid biosynthesis and the
amounts of bile acids entering the colon (218). Indeed, a
recent phase II clinical trial at Imperial College London
demonstrated OCA to be effective in increasing serum
FGF19 levels and alleviating diarrheal symptoms in BAD
patients (480).
The crystal structure of TGR5 has not yet been resolved
with the result that the identification and development of
agonists for this receptor is currently lagging somewhat
behind that of the FXR. Leading the way is INT-777, a
semi-synthetic agonist which displays an affinity of 0.8 M
for TGR5 compared with 100 M for FXR in cell-based
assays (354). Work in preclinical models suggests that, sim-
ilar to FXR agonists, drugs which target TGR5 have great
promise for treatment of hepatic and metabolic disorders
(70, 259). In the intestine, TGR5 appears to have important
roles in regulating motility, secretion, and mucosal inflam-
matory responses (8, 50, 72, 109, 393, 488), suggesting that
drugs targeting the receptor may find future uses in treat-
ment of intestinal disorders, such as IBS and IBD. However,
with first-in-man studies of TGR-5 targeted drugs still lack-
ing at the time of writing, it would seem that such therapeu-
tics are still some way off.
B. UDCA
As the primary component of bear bile, UDCA has been in
use in Traditional Chinese Medicine for centuries to treat a
range of maladies, including liver and intestinal disorders,
poor vision, convulsions, and impotency, to name but a few
(118). In Western medicine, UDCA has been in use for
many years in the treatment of liver diseases, especially PBC
(97). It has also been closely studied for its potential in
preventing the development of CRC associated with pri-
mary sclerosing cholangitis and IBD. In this respect, low-
dose UDCA has been reported to exert chemopreventive
actions (38, 420), while its use at high doses over prolonged
periods of time may actually increase the incidence of CRC
(112). In clinical and preclinical studies, UDCA has shown
promise in treatment of numerous extrahepatic conditions,
including IBD (466). In various animal models of IBD,
UDCA or its taurine-conjugated derivative reduces disease
activity, attenuates mucosal cytokine levels, inhibits release
of antimicrobial peptides, and prevents apoptosis (245,
280, 461, 509). UDCA also acts on mucosal immune cells
to dampen their activation and the release of proinflamma-
tory cytokines (330). Interestingly, although the primary
metabolite of UDCA, LCA, is typically regarded as the most
toxic of the colonic bile acids, our recent studies suggest
that metabolism to LCAmay, in fact, be required for the full
expression of the protective effects of UDCA in intestinal
inflammation (489). It is clear that considerable work is still
required to elucidate relationships between UDCA, its me-
tabolites, the microbiota, and mucosal inflammatory re-
sponses.
C. ASBT inhibitors
Chronic idiopathic constipation (CIC) is an extremely com-
mon condition, which affects ~25% of the general popula-
tion and for which currently available treatments are often
unsatisfactory (478). A new approach to therapy currently
in clinical trials involves inhibition of the ileal ASBT. ASBT
is localized on the apical membrane of enterocytes in the
terminal ileum and plays a central role in absorption of
conjugated bile acids from the intestinal lumen (90). Inhi-
bition of ASBT reduces ileal absorption of bile acids result-
ing in increased hepatic synthesis and increased delivery to
the colon, where they promote fluid secretion and motility
(2). Elobixibat is a potent and selective inhibitor of IBAT,
which has been shown in clinical trials to reduce colonic
transit time, increase the number of spontaneous bowel
movements, and improve stool consistency (68, 418, 501).
Elobixibat has limited systemic bioavailability, thereby re-
ducing the potential for side effects and drug interactions.
The use of elobixibatmay also have potential added benefits
in patients with metabolic disorders, since inhibition of ileal
bile acid reabsorption decreases activation of the FXR/
FGF19 axis, consequently upregulating bile acid synthesis
and reducing serum cholesterol. At the same time elobixibat
also increases plasma levels of the incretin GLP-1, an effect
that is likely due to luminal bile acids activating TGR5 on
enteroendocrine L-cells (389). Such metabolic sequelae of
ASBT inhibition suggest that drugs, such as elobixibat, may
be of particular benefit to patients with either dyslipidemia
or diabetes mellitus, both of which can be comorbidities of
chronic constipation.
D. Bile Acid Sequestrants
Bile acid sequestrants (BAS; e.g., cholestyramine, colestipol,
and colesevelam) are anionic nondigestible resins which
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bind bile acids in the intestine, forming insoluble complexes
which are then excreted in the feces. Originally developed
for treatment of hypercholesterolemia, cholestyramine acts
by disrupting the EHC, resulting in increased conversion of
cholesterol to bile acids in hepatocytes, thereby lowering
plasma LDL-C (287). BAS are also effective in improving
glucose homeostasis through induction of TGR5-mediated
GLP-1 release in the distal intestine (371, 427). As a conse-
quence of these metabolic effects, BAS are currently receiv-
ing a great deal of interest for their potential as new treat-
ments for obesity and type 2 diabetes (257, 431). Given that
they bind luminal bile acids, one might expect that BAS
should also be useful in treating bile acid diarrhea, and
indeed, this is the case, as demonstrated by several clinical
studies (reviewed in Refs. 52, 481). BAS have also been
found to be of benefit in treating diarrhea associated with
Clostridium difficile infection, microscopic colitis, and CD
(29, 289, 329). BAS are generally safe to use, but cholesty-
ramine and colestipol are often poorly tolerated due to poor
palatability and frequent gastrointestinal side effects, such
as constipation, abdominal pain, bloating, and flatulence
(260). In contrast, colesevelam is available in tablet form
and has only mild gastrointestinal adverse effects. Nonethe-
less, BAS can have significant drug-drug interactions which
limits their therapeutic usefulness. To overcome some of
these issues, a colonic release formulation of cholesty-
ramine, known as A3384, has been recently developed and
in clinical trials was found to be well-tolerated and effica-
cious in reducing diarrhea (17).
E. Dietary Manipulation
The saying that “you are what you eat” is certainly true
when it comes to the makeup of our colonic bile acid sig-
nature. The Western high-fat/high-sugar/low-fiber diet,
which is associated with the development of many diseases,
including CRC, IBD, IBS, obesity, and diabetes, is also as-
sociated with a significantly altered bile acid signature.
These changes occur, at least partly, as a consequence of
increased hepatic bile acid biosynthesis in response to the
high intake of fat and partly to their altered metabolism due
to the presence of a “Westernized” microbiota in the colon
(i.e., a high firmicutes-to-bacterioidetes ratio) (86, 318,
455, 472). Thus studies in mice have shown that consump-
tion of a high-fat diet results in enhanced gut permeability,
associated with increased levels of luminal bile acids, along
with an increase in the ratio of DCA to UDCA (39, 316,
433, 434). Furthermore, studies suggest that Western diets,
with their high meat intake, favor taurine rather than gly-
cine conjugation of bile acids, leading an increase in tau-
rine-metabolizing bacteria in the colon, such as B. Wad-
sworthia. In turn, increased production of hydrogen sulfide
has been implicated in the pathogenesis of CRC and UC
(100, 383). Thus avoidance of aWestern diet in favor of one
containing less fat and more fiber appears to be the simplest
approach to modulate the intestinal bile acid signature for
prevention of intestinal diseases (332, 383, 459).
F. Probiotics
Another way in which the luminal bile acid signature can be
manipulated to treat or prevent disease is through the use of
neutraceuticals, such as probiotics (197). To date, this ap-
proach has been most studied in the context of metabolic
diseases, with probiotics, such as L. rhamnosus GG and L.
Reuteri, being shown to prevent hypercholesterolemia and
obesity in various preclinical and clinical settings (195,
281). Key to the positive effects of probiotics on lipid and
cholesterol metabolism appears to be their expression of
BSH enzymes, associated changes in conjugation/deconju-
gation of the bile acid signature, with consequent altera-
tions in the ileal FXR/FGF19 axis (99, 196, 199). Thus,
while there is still a great deal to be learned of the mecha-
nisms and pathways involved, there appears to be some
potential in employing probiotics as an approach to modu-
late the luminal bile acid signature to drive a more positive
metabolic phenotype. Studies in animal models suggest that
such an approach may also be useful for the treatment of
intestinal diseases. For example, the BSH activity of Lacto-
bacillus johnsonii La1 has been shown to prevent Giardia
growth by producing secondary bile acids that are toxic to
the parasite (451), while the 7-dehydroxylating activity of
Clostridium scindens creates a bile acid signature in mice
that prevents C. difficile infection (49). Whether probiotic-
driven alterations in luminal bile acid composition might be
beneficial in patients with IBD remains to be determined,
but available evidence would suggest that this should be the
case. Bile acid modifying genes, including BSHs and 7-
dehydroxylases, are significantly altered in the microbiota
of patients with UC and CD, likely underlying the genera-
tion of bile acid signatures with high levels of primary,
conjugated, and sulfated bile acids (107, 241). While sys-
tematic analysis of clinical trials suggests that probiotics can
have varying degrees of efficacy in alleviating IBD symp-
toms (133), studies employing bacterial strains specifically
selected for their BSH or 7-dehydroxylating activities are
still required. Another exciting approach that is likely to be
an area of increasing research interest in the coming years is
the use of prebiotics (e.g., rice bran) to modulate the micro-
biota and bile acid signature for therapeutic purposes
(299a, 320, 324).
G. Fecal Microbial Transfer
Fecal microbial transplantation (FMT) is defined as the
transfer of fecal material containing bacteria from a healthy
donor into a diseased recipient. Although used for centuries
in traditional Eastern medicines, FMT is only recently gain-
ing acceptance as an approach to therapy in Western soci-
eties (243, 366). FMT has been shown to be highly effective
in treatment of recurrent C. difficile infection (CDI), with a
“clinical cure” rate of 90% in most studies conducted to
date (222, 226, 233). As might be expected, FMT dramat-
ically alters the bile acid signature in CDI recipients from
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one which contains high concentrations of primary bile ac-
ids, to one which contains predominantly secondary bile
acids (495). Furthermore, recent studies suggest that FMT-
induced changes in the colonic bile acid signature alone are
sufficient to prevent C. difficile growth (495). These data
clearly demonstrate the potential for using FMT as a ther-
apeutic tool to manipulate luminal levels of bile acids in
disease treatment. As a consequence of its success in CDI,
FMT is currently under investigation for numerous other
intestinal disorders, including IBD, IBS, and pancreatitis. As
these studies progress, it will be critically important to mon-
itor the role of bile acids in mediating any beneficial actions
that are observed. Indeed, the potential for orally adminis-
tered bile acids as an alternative to FMT is supported by a
recent study demonstrating that UDCA inhibits the germi-
nation of C. difficile spores in vitro and effectively induced
and maintained remission from recurrent CDI in a human
subject (495). Further studies suggest that such a therapeu-
tic approach could also be taken a step further through the
development of synthetic bile acid analogues that prevent
C. difficile growth but which are restricted to the gut lumen
(436).
VIII. CONCLUSIONS
In this review we set out to describe some of the exciting
advances that have been made over the past two decades
with respect to our understanding of how bile acids regulate
intestinal epithelial physiology in health and disease. Driven
by the discovery of new receptors for bile acids, our knowl-
edge of how epithelial cells sense changes in luminal bile
acid signatures and the molecular pathways that are conse-
quently activated is rapidly developing. At the same time,
the endogenous and exogenous factors that bring about
changes in the size and makeup of the bile acid pool are
becoming increasingly understood. However, there is still
much to be learned. The growing appreciation of the role
that bile acids play in health and disease, alongwith increas-
ing interest within the Pharma sector for exploiting bile
acids in treatment of intestinal and extraintestinal disor-
ders, ensures that this will remain an area of intense re-
search activity for years to come. Particularly important,
and equally challenging, is the development of our under-
standing of how bile acids act as signaling intermediates
between us as humans and the microbes that colonize our
guts. Cracking the code of this intra-kingdom dialogue and
how epithelial cells integrate and transduce these signals
into biological responses will be sure to provide valuable
new targets for therapeutic intervention. It seems certain
that whether it be through the use of receptor selective
drugs, dietary manipulation, pre/probiotics, or fecal trans-
plants, the coming years will see the emergence of new
approaches to manipulate luminal bile acid signatures and
associated epithelial signaling pathways in treatment and
prevention of disease.
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